{"content":"<li class=\"n-box-item date-title\" data-end=\"1562731199\" data-start=\"1562644800\" data-txt=\"Monday, December 23, 2019\">Tuesday, July  9, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3476677\" data-ts=\"1562711476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDD\" target=\"_blank\">PDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476677-j-p-morgan-starts-pinduoduo-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.P. Morgan starts Pinduoduo at Underweight</a></h4><ul>    <li>J.P. Morgan has initiated coverage of Pinduoduo (NASDAQ:<a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo Inc.'>PDD</a>) at Underweight, a rare bearish call against nearly two dozen Buy-equivalent ratings on the Street.</li>    <li>It's set a price target of $17, implying 17% downside from the closing price.</li>    <li>And along with sell-side analysts that <a href=\"https://seekingalpha.com/symbol/PDD/ratings/sell-side-ratings\" target=\"_blank\">rate it Buy on average</a>, <a href=\"https://seekingalpha.com/symbol/PDD/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Bullish as well</a>.</li>    <li>Pinduoduo is <font color=\"red\">down 1.6%</font> postmarket in Nasdaq trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476677\" data-linked=\"J.P. Morgan starts Pinduoduo at Underweight\" data-tweet=\"$PDD - J.P. Morgan starts Pinduoduo at Underweight https://seekingalpha.com/news/3476677-j-p-morgan-starts-pinduoduo-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3476677-j-p-morgan-starts-pinduoduo-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476675\" data-ts=\"1562711001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476675-zillow-redfin-up-suntrust-launches-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow, Redfin up as SunTrust launches at Buy</a></h4><ul>   <li>Shares in Zillow Group and Redfin are higher after hours as SunTrust Robinson Humphrey launches coverage on each company at Buy.</li>    <li>SunTrust set a price target on Redfin of $23, implying 28% upside. On that stock, sell-side analysts rate it <a href=\"https://seekingalpha.com/symbol/RDFN/ratings/sell-side-ratings\" target=\"_blank\">Outperform on average</a> while <a href=\"https://seekingalpha.com/symbol/RDFN/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>.</li>    <li>As for Zillow, it's established a target of $58, implying 17% upside. Sell-side analysts <a href=\"https://seekingalpha.com/symbol/ZG/ratings/sell-side-ratings\" target=\"_blank\">rate it Hold</a>; <a href=\"https://seekingalpha.com/symbol/ZG/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>; and the stock has a <a href=\"https://seekingalpha.com/symbol/ZG/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/RDFN' title='Redfin Corporation'>RDFN</a> <font color=\"green\">+0.6%</font>; <a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a> <font color=\"green\">+1.8%</font>; <a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a> <font color=\"green\">+0.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476675\" data-linked=\"Zillow, Redfin up as SunTrust launches at Buy\" data-tweet=\"$RDFN $Z $ZG - Zillow, Redfin up as SunTrust launches at Buy https://seekingalpha.com/news/3476675-zillow-redfin-up-suntrust-launches-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3476675-zillow-redfin-up-suntrust-launches-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476670\" data-ts=\"1562708737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQT\" target=\"_blank\">EQT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476670-rice-brothers-win-votes-to-take-control-of-eqt-board-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rice brothers win votes to take control of EQT board - Reuters</a></h4><ul><li>EQT Corp. (NYSE:<a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a>) <font color=\"green\">+3.4%</font> after-hours as Reuters reports Toby and Derek Rice have gained enough shareholder votes to <a href=\"https://www.reuters.com/article/eqt-corp-rice-group-proxy/rice-group-set-to-take-control-of-eqt-board-in-proxy-contest-source-idUSL2N24A19E\" target=\"_blank\">win control of the company's board</a>, two years after selling the company.</li><li>If investors vote the Rice brothers in, \"the kind of change they are voting for is a pretty <a href=\"https://finance.yahoo.com/news/two-brothers-lead-showdown-u-090000335.html\" target=\"_blank\">dramatic shakeup</a>,\" says Tudor Pickering Holt's Sameer Panjwani. \"The message they have been campaigning for has been enhanced free cash flow, and that is really the main thing the market is looking for today. That\u2019s definitely why they have traction.\"</li><li>Electing the Rice slate would result in \"a weaker board and managerial chaos,\" and Toby Rice is not fit to lead a public company, EQT has said.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476670\" data-linked=\"Rice brothers win votes to take control of EQT board - Reuters\" data-tweet=\"$EQT - Rice brothers win votes to take control of EQT board - Reuters https://seekingalpha.com/news/3476670-rice-brothers-win-votes-to-take-control-of-eqt-board-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3476670-rice-brothers-win-votes-to-take-control-of-eqt-board-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476666\" data-ts=\"1562707939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476666-hele-wdfc-and-levi-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HELE, WDFC and LEVI among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a> <font color=\"green\">+7.4%</font>. <a href='https://seekingalpha.com/symbol/WDFC' title='WD-40 Company'>WDFC</a> <font color=\"green\">+3.5%</font>. <a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a> <font color=\"green\">+1.5%</font>. <a href='https://seekingalpha.com/symbol/MLNT' title='Melinta Therapeutics, Inc.'>MLNT</a> <font color=\"green\">+1.4%</font>. <a href='https://seekingalpha.com/symbol/AUO' title='AU Optronics Corp.'>AUO</a> <font color=\"green\">+1.4%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a> <font color=\"red\">-19.9%</font>. <a href='https://seekingalpha.com/symbol/LEVI' title='Levi Strauss & Co.'>LEVI</a> <font color=\"red\">-5.6%</font>.<a href='https://seekingalpha.com/symbol/CVM' title='CEL-SCI Corporation'>CVM</a> <font color=\"red\">-2.3%</font>. <a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color=\"red\">-1.6%. </font><a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a> <font color=\"red\">-1.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476666\" data-linked=\"HELE, WDFC and LEVI among after hour movers\" data-tweet=\"$HELE $WDFC $OCX - HELE, WDFC and LEVI among after hour movers https://seekingalpha.com/news/3476666-hele-wdfc-and-levi-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476666-hele-wdfc-and-levi-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476663\" data-ts=\"1562707463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476663-t-mobile-to-join-s-and-p-500-tmus-s-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T-Mobile to join S&amp;P 500; TMUS, S gain</a></h4><ul>   <li>T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) will <a href=\"https://us.spindices.com/documents/indexnews/announcements/20190709-957359/957359_hat5mobile.pdf?force_download=true\" target=\"_blank\">join the S&amp;P 500</a> -- and no, not because it's suddenly bigger by about one Sprint.</li>    <li>The wireless carrier will replace Red Hat in the index, after IBM closed on its deal for Red Hat today.</li>    <li>The move is effective prior to the open of trading on Monday, July 15.</li>    <li>Shares are <font color=\"green\">up 3.4%</font> after hours; purported merger partner Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) is <font color=\"green\">up 1.8%</font> postmarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476663\" data-linked=\"T-Mobile to join S&amp;P 500; TMUS, S gain\" data-tweet=\"$TMUS $S - T-Mobile to join S&amp;P 500; TMUS, S gain https://seekingalpha.com/news/3476663-t-mobile-to-join-s-and-p-500-tmus-s-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3476663-t-mobile-to-join-s-and-p-500-tmus-s-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476662\" data-ts=\"1562707134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476662-harmonicplus-4_5-on-comcast-license-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmonic +4.5% on Comcast license deal</a></h4><ul>   <li>Harmonic (NASDAQ:<a href='https://seekingalpha.com/symbol/HLIT' title='Harmonic Inc.'>HLIT</a>) is <font color=\"green\">up 4.5%</font> after hours following a filing where it discloses that Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) has entered an <a href=\"https://seekingalpha.com/filing/4560955\" target=\"_blank\">enterprise license deal</a> for its CableOS software.</li>    <li>Comcast affiliate Comcast Cable Communications Management committed to $175M in software license fees over a four-year term.</li>    <li>CCCM will pay an initial $50M of the fees in 2019.</li>    <li>In consideration for the deal, Harmonic has deemed that all warrant shares it previously issued to Comcast (the right to purchase up to 7.82M shares at an exercise price of $4.76) are fully vested and exercisable.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476662\" data-linked=\"Harmonic +4.5% on Comcast license deal\" data-tweet=\"$HLIT $CMCSA - Harmonic +4.5% on Comcast license deal https://seekingalpha.com/news/3476662-harmonicplus-4_5-on-comcast-license-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3476662-harmonicplus-4_5-on-comcast-license-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476651\" data-ts=\"1562705760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HELE\" target=\"_blank\">HELE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476651-helen-of-troyplus-7-ah-after-q1-beat-raised-fy20-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helen of Troy +7% AH after Q1 beat; raised FY20 earnings guidance</a></h4><ul><li>Helen of Troy (NASDAQ:<a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a>) <font color=\"green\">+7.2%</font> AH following a big FQ1 beat, while raising FY20 earnings above analyst consensus.</li><li>HELE now <a href=\"https://seekingalpha.com/pr/17566624-helen-troy-limited-reports-first-quarter-fiscal-2020-results\" target=\"_blank\">expects</a> FY20 Non-GAAP EPS in the range of $8.40 - $8.65 vs. a consensus of $8.37; FY20 Revenue in the range of $1.59B - $1.62B  vs. a consensus of $1.59B.</li><li>Julien R. Mininberg, Chief Executive Officer; \"..Continued investment behind our Leadership Brands paid off handsomely, with net sales growth of 7.4% in the quarter. We continue to gain significant ground online with strong double-digit growth to now represent 23% of consolidated sales..\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3476621-helen-troy-eps-beats-0_37-beats-revenue\" target=\"_blank\">Helen of Troy EPS beats by $0.37, beats on revenue</a> (July 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476651\" data-linked=\"Helen of Troy +7% AH after Q1 beat; raised FY20 earnings guidance\" data-tweet=\"$HELE - Helen of Troy +7% AH after Q1 beat; raised FY20 earnings guidance https://seekingalpha.com/news/3476651-helen-of-troyplus-7-ah-after-q1-beat-raised-fy20-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3476651-helen-of-troyplus-7-ah-after-q1-beat-raised-fy20-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476645\" data-ts=\"1562705419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDFC\" target=\"_blank\">WDFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476645-on-wdminus-40s-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on WD-40&#39;s Q3 results</a></h4><ul><li>WD-40 (NASDAQ:<a href='https://seekingalpha.com/symbol/WDFC' title='WD-40 Company'>WDFC</a>) reported Q3 net sales growth of 6.5% Y/Y to $113.99M, with America\u2019s at $52.97M (flat); EMEA $44.55M (+13% Y/Y) and Asia-Pacific at $16.47M (+14% Y/Y).</li><li>Product sales: Maintenance products $104.53M (+6% Y/Y), reflecting increased sales of WD-40 Multi-Use Product within the EMEA and Asia-Pacific segments and increased sales of WD-40 Specialist in the Americas segment; and Homecare and cleaning products $9.46M (+16% Y/Y) reflecting higher sales of 1001 Carpet Fresh in the United Kingdom.</li><li>Q3 Gross margin <font color=\"red\">declined by 34 bps</font> to 54.5%; and operating margin <font color=\"red\">declined by 51 bps</font> to 20.4%.</li><li>Net cash provided by operating activities YTD was $36.27M, compared to $41.59M a year ago.</li><li>Company repurchased 132,184 shares at a total cost of $22.4M under the $75M plan, from September 1, 2018 through May 31, 2019.</li><li><strong>FY19 Guidance:</strong> Net Sales $425M to $437M (growth of 4% to 7%); Gross margin of ~55%; forecasts net income of $63.3MM-$64.4M (prior $62.2M-$63.2M); and diluted EPS of $4.58-$4.65 (prior $4.51-$4.58).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3476622-wdminus-40-eps-beats-0_08-beats-revenue\" target=\"_blank\">WD-40 EPS beats by $0.08, beats on revenue</a> (July 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476645\" data-linked=\"More on WD-40&#39;s Q3 results\" data-tweet=\"$WDFC - More on WD-40&#39;s Q3 results https://seekingalpha.com/news/3476645-on-wdminus-40s-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3476645-on-wdminus-40s-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476643\" data-ts=\"1562704829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OASM\" target=\"_blank\">OASM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476643-oasmia-cuts-ties-former-executive-chairman-over-questionable-transactions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasmia cuts ties with former executive chairman over questionable transactions</a></h4><ul><li>Oasmia Pharmaceutical AB (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical AB &#40;publ&#41;'>OASM</a>) reports that it has <a href=\"https://www.oasmia.com/en/oasmia-discontinues-cooperation-with-former-executive-chairman/\" target=\"_blank\">terminated </a>its \"engagement and cooperation\" with former executive chairman Julian Aleksov without further pay.</li><li>The company took action following a <a href=\"https://www.oasmia.com/en/the-board-of-oasmia-has-decided-to-report-certain-transactions-to-the-swedish-economic-crime-authority-and-to-appoint-a-special-examiner/\" target=\"_blank\">tax audit</a> that revealed missing funds connected to suspicious transactions between Oasmia and companies controlled by Mr. Aleksov and his former father in-law.</li><li>The board has reported the matter to the Swedish Economic Crime Authority.</li><li>Shares are down <font color=\"red\">3%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476643\" data-linked=\"Oasmia cuts ties with former executive chairman over questionable transactions\" data-tweet=\"$OASM - Oasmia cuts ties with former executive chairman over questionable transactions https://seekingalpha.com/news/3476643-oasmia-cuts-ties-former-executive-chairman-over-questionable-transactions?source=tweet\" data-url=\"https://seekingalpha.com/news/3476643-oasmia-cuts-ties-former-executive-chairman-over-questionable-transactions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476635\" data-ts=\"1562703468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEVI\" target=\"_blank\">LEVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476635-post-earnings-drop-for-levi-strauss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings drop for Levi Strauss</a></h4><ul><li>Levi Strauss (NYSE:<a href='https://seekingalpha.com/symbol/LEVI' title='Levi Strauss & Co.'>LEVI</a>) is <font color=\"red\">down 4.1%</font> in AH trading after falling short with FQ2 sales and EPS.</li><li>Adjusted EBIT was down 4% during the quarter, reflecting unfavorable currency swings and the planned deferral of higher advertising spend from FQ1. Higher promotion expenses also factored in.</li><li>Shares of LEVI were up 11% over the last week into the earnings report as traders came in confident.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3476630-levi-strauss-eps-misses-0_31-misses-revenue\" target=\"_blank\">Levi Strauss EPS misses by $0.31, misses on revenue</a> (July 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476635\" data-linked=\"Post-earnings drop for Levi Strauss\" data-tweet=\"$LEVI - Post-earnings drop for Levi Strauss https://seekingalpha.com/news/3476635-post-earnings-drop-for-levi-strauss?source=tweet\" data-url=\"https://seekingalpha.com/news/3476635-post-earnings-drop-for-levi-strauss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476621\" data-ts=\"1562702818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HELE\" target=\"_blank\">HELE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476621-helen-of-troy-eps-beats-0_37-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helen of Troy EPS beats by $0.37, beats on revenue</a></h4><ul><li>Helen of Troy (NASDAQ:<a href='https://seekingalpha.com/symbol/HELE' title='Helen of Troy Limited'>HELE</a>): Q1 Non-GAAP EPS of $2.06 <font color=\"green\">beats by $0.37</font>; GAAP EPS of $1.61 <font color=\"green\">beats by $0.18</font>.</li><li>Revenue of $376.3M (+6.1% Y/Y) <font color=\"green\">beats by $24.76M</font>.</li><li>Shares <font color=\"green\">+2.4%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17566624-helen-troy-limited-reports-first-quarter-fiscal-2020-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3476621\" data-linked=\"Helen of Troy EPS beats by $0.37, beats on revenue\" data-tweet=\"$HELE - Helen of Troy EPS beats by $0.37, beats on revenue https://seekingalpha.com/news/3476621-helen-of-troy-eps-beats-0_37-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3476621-helen-of-troy-eps-beats-0_37-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476611\" data-ts=\"1562701656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476611-amarin-down-5-on-third-citizen-petition-to-invalidate-key-vascepa-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin down 5% on third citizen petition to invalidate key Vascepa patent</a></h4><ul><li>Amarin (<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a> <font color=\"red\">-5.1%</font>) is down on more than double normal volume in what appears to be profit-taking after its <font color=\"green\">33%</font> rally since late June.</li><li>Many observers are attributing today's drop to the filing of a third Citizen Petition by Medical Research Collaborative, LLC requesting that the company's U.S. Patent No. 8,188,146 covering the composition of highly purified ethyl eicosapentaenoic acid &#40;EPA&#41; and other EPA derivatives, be removed from the FDA's Orange Book (ultra-pure omega-3 fatty acid is the active ingredient in Vascepa).</li><li>On May 31, 2016, the FDA awarded Amarin five years of New Chemical Entity &#40;NCE&#41; exclusivity for Vascepa, meaning that icosapent ethyl should not contain any active moiety previously approved by the agency. As the patent title states, though, icosapent ethyl is an ethyl ester of EPA. GlaxoSmithKline's Lovaza (omega-3-acid ethyl esters) is a combination of seven ethyl esters of omega-3 fatty acids so many have <a href=\"https://www.pepperlaw.com/publications/fda-is-evolving-on-qualifications-for-new-chemical-entity-2016-09-07/\" target=\"_blank\">argued </a>that the agency erred in granting NCE exclusivity for Vascepa, the removal of which would open the floodgates for competitors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476611\" data-linked=\"Amarin down 5% on third citizen petition to invalidate key Vascepa patent\" data-tweet=\"$AMRN - Amarin down 5% on third citizen petition to invalidate key Vascepa patent https://seekingalpha.com/news/3476611-amarin-down-5-on-third-citizen-petition-to-invalidate-key-vascepa-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3476611-amarin-down-5-on-third-citizen-petition-to-invalidate-key-vascepa-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>113&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476610\" data-ts=\"1562701318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476610-copper-focused-names-slide-amid-retreating-price-higher-dollar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Copper-focused names slide amid retreating price, higher dollar</a></h4><ul><li>Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color=\"red\">-3.1%</font>) and other base metal producers fall sharply as <a href=\"https://www.reuters.com/article/global-metals/metals-copper-extends-losses-as-markets-await-firm-u-s-china-deal-idUSL4N24A1VW\" target=\"_blank\">copper prices tumble to a three-week low</a> under pressure from a stronger dollar even with trade talks resuming between the U.S. and China, settling <font color=\"red\">-1.2%</font> to $5,822/oz. on the London Metal Exchange after touching its weakest level since June 17.</li><li>\"We need to see some firm agreements,\" says Danske Bank commodities analyst Jens Pedersen. \"We had the [U.S.-China] ceasefire, which means things are unlikely to get worse, but they are still quite bad.\"</li><li>The discount between LME cash copper and the three-month contract  hovered near a two-week high at $17.95/mt, indicating  plentiful nearby supply.</li><li>Also lower: <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color=\"red\">-1.6%</font>, <a href='https://seekingalpha.com/symbol/SCCO' title='Southern Copper Corporation'>SCCO</a> <font color=\"red\">-1.6%</font>, <a href='https://seekingalpha.com/symbol/TRQ' title='Turquoise Hill Resources Ltd.'>TRQ</a> <font color=\"red\">-6.8%.</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJCTF' title='iPath DJ-UBS Copper Total Return Sub-Index ETN'>OTCPK:JJCTF</a>, <a href='https://seekingalpha.com/symbol/COPX' title='Global X Copper Miners ETF'>COPX</a>, <a href='https://seekingalpha.com/symbol/DBB' title='Invesco DB Base Metals ETF'>DBB</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/BOM' title='DB Base Metals Double Short ETN'>BOM</a>, <a href='https://seekingalpha.com/symbol/BDD' title='DB Base Metals Double Long ETN'>BDD</a>, <a href='https://seekingalpha.com/symbol/JJM' title='iPath DJ-UBS Industrial Metals Total Return Sub-Index ETN'>JJM</a>, <a href='https://seekingalpha.com/symbol/BOS' title='DB Base Metals Short ETN'>BOS</a>, <a href='https://seekingalpha.com/symbol/RJZ' title='ELEMENTS Rogers International Commodity Metal ETN'>RJZ</a>, <a href='https://seekingalpha.com/symbol/UBM' title='UBS ETRACS CMCI Industrial Metals Total Return ETN'>UBM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3476610\" data-linked=\"Copper-focused names slide amid retreating price, higher dollar\" data-tweet=\"$FCX $TECK $SCCO - Copper-focused names slide amid retreating price, higher dollar https://seekingalpha.com/news/3476610-copper-focused-names-slide-amid-retreating-price-higher-dollar?source=tweet\" data-url=\"https://seekingalpha.com/news/3476610-copper-focused-names-slide-amid-retreating-price-higher-dollar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476606\" data-ts=\"1562699679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LHX\" target=\"_blank\">LHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476606-l3harris-added-to-conviction-buy-list-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L3Harris added to Conviction Buy List at Goldman</a></h4><ul><li>Newly merged L3Harris (<a href='https://seekingalpha.com/symbol/LHX' title='L3Harris Technologies, Inc.'>LHX</a> <font color=\"green\">+3%</font>) leaps higher after Goldman Sachs analyst Noah Poponak reinstates coverage with a <a href=\"https://thefly.com/thestreet/realmoney/index.php/LHXid2930411/LHX-LHarris-reinstated-with-a-Buy-added-to-Conviction-List-at-Goldman-Sachs\" target=\"_blank\">Buy rating</a> with a $240 price target and adds the stock to the firm's Conviction Buy List.</li><li>Poponak thinks LHX is set to deliver upside to growth expectations \"quickly\" given recent contract wins and current Department of Defense outlay strength, and sees upside potential from the merger integration.</li><li>LHX's average <a href=\"https://seekingalpha.com/symbol/LHX/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform but its <a href=\"https://seekingalpha.com/symbol/LHX/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476606\" data-linked=\"L3Harris added to Conviction Buy List at Goldman\" data-tweet=\"$LHX - L3Harris added to Conviction Buy List at Goldman https://seekingalpha.com/news/3476606-l3harris-added-to-conviction-buy-list-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3476606-l3harris-added-to-conviction-buy-list-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476600\" data-ts=\"1562698616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476600-acia-qtt-and-gtt-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ACIA, QTT and GTT among tech movers</a></h4><ul><li><strong>Gainers:</strong> Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications, Inc.'>ACIA</a>) <font color=\"green\">+35%</font>. Resonant (NASDAQ:<a href='https://seekingalpha.com/symbol/RESN' title='Resonant Inc.'>RESN</a>) <font color=\"green\">+13%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao Inc.'>QTT</a>) <font color=\"green\">+13%</font>. Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) <font color=\"green\">+12%</font>. TransAct Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TACT' title='TransAct Technologies Incorporated'>TACT</a>) <font color=\"green\">+12%</font>.</li> <li><strong>Losers</strong>: Jiayin Group (NASDAQ:<a href='https://seekingalpha.com/symbol/JFIN' title='Jiayin Group Inc.'>JFIN</a>) <font color=\"red\">-12%</font>. Technical Communications Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"red\">-10%</font>. Moxian (NASDAQ:<a href='https://seekingalpha.com/symbol/MOXC' title='Moxian, Inc.'>MOXC</a>) <font color=\"red\">-9%</font>. Streamline Health Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a>) <font color=\"red\">-8%</font>. GTT Communications (NYSE:<a href='https://seekingalpha.com/symbol/GTT' title='GTT Communications, Inc.'>GTT</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476600\" data-linked=\"ACIA, QTT and GTT among tech movers\" data-tweet=\"$ACIA $RESN $QTT - ACIA, QTT and GTT among tech movers https://seekingalpha.com/news/3476600-acia-qtt-and-gtt-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476600-acia-qtt-and-gtt-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476599\" data-ts=\"1562697496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BASFY\" target=\"_blank\">BASFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476599-basfs-weak-guidance-weighs-on-chemical-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BASF&#39;s weak guidance weighs on chemical stocks</a></h4><ul><li>U.S. chemical makers slide after German giant BASF (<a href='https://seekingalpha.com/symbol/BASFY' title='BASF SE'>OTCQX:BASFY</a> <font color=\"green\">+2.4%</font>) <a href=\"https://seekingalpha.com/news/3476284-basf-expects-q2-ebit-special-items-expectations-lowered-fy19-outlook\" target=\"_blank\">cut its profit forecast</a> yesterday, citing the continuing trade dispute between the U.S. and China as well as sluggish demand in the auto market.</li><li>Chemical stocks trading lower include Dow (<a href='https://seekingalpha.com/symbol/DOW' title='Dow Inc.'>DOW</a> <font color=\"red\">-1.2%</font>), DuPont (<a href='https://seekingalpha.com/symbol/DD' title='DuPont de Nemours, Inc.'>DD</a> <font color='red'>-2.8%</font>), LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color=\"red\">-3.5%</font>), Hunstman (<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color=\"red\">-0.3%</font>), Methanex (<a href='https://seekingalpha.com/symbol/MEOH' title='Methanex Corporation'>MEOH</a> <font color=\"red\">-1.8%</font>), Eastman Chemical (<a href='https://seekingalpha.com/symbol/EMN' title='Eastman Chemical Company'>EMN</a> <font color=\"red\">-1.3%</font>), Cabot (<a href='https://seekingalpha.com/symbol/CBT' title='Cabot Corporation'>CBT</a> <font color=\"red\">-1.6%</font>), Olin (<a href='https://seekingalpha.com/symbol/OLN' title='Olin Corporation'>OLN</a> <font color=\"red\">-2.1%</font>), PPG Industries (<a href='https://seekingalpha.com/symbol/PPG' title='PPG Industries, Inc.'>PPG</a> <font color=\"red\">-0.7%</font>), W.R. Grace (<a href='https://seekingalpha.com/symbol/GRA' title='W. R. Grace & Co.'>GRA</a> <font color=\"red\">-1.1%</font>), Westlake Chemical (<a href='https://seekingalpha.com/symbol/WLK' title='Westlake Chemical Corporation'>WLK</a> <font color=\"red\">-0.5%</font>), Air Products and Chemicals (<a href='https://seekingalpha.com/symbol/APD' title='Air Products and Chemicals, Inc.'>APD</a> <font color=\"red\">-0.9%</font>) and Celanese (<a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a> <font color=\"red\">-0.4%</font>).</li><li>Chemours (<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a> <font color=\"green\">+1%</font>) is rebounding a bit after plunging 7% yesterday.</li><li>BASF's preliminary figures showed EBIT likely fell by nearly 50% in Q2 and global auto production declined by ~6% in H1 2019, with production in China falling by more than twice as much.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476599\" data-linked=\"BASF&#39;s weak guidance weighs on chemical stocks\" data-tweet=\"$BASFY $DOW $LYB - BASF&#39;s weak guidance weighs on chemical stocks https://seekingalpha.com/news/3476599-basfs-weak-guidance-weighs-on-chemical-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3476599-basfs-weak-guidance-weighs-on-chemical-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476593\" data-ts=\"1562696629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476593-apple-amazon-facebook-google-set-to-testify-in-house-panel-hearing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple, Amazon, Facebook, Google set to testify in House panel hearing</a></h4><ul>   <li>Tech giants including Apple (<a href=\"http://seekingalpha.com/symbol/AAPL\" target=\"_blank\">AAPL</a> <font color=\"green\">+0.7%</font>), Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color=\"green\">+1.8%</font>), Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color=\"green\">+1.6%</font>) and Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color=\"green\">+0.9%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color=\"green\">+0.9%</font>) will be <a href=\"https://www.washingtonpost.com/technology/2019/07/09/apple-amazon-facebook-google-testify-congress-antitrust/?utm_term=.8470c6ad41e8\" target=\"_blank\">called to testify</a> at next week's House Judiciary Committee antitrust hearing.</li>    <li>That follows moves by regulators to divide up the four among themselves to spread investigative power widely as the government probes public concerns into the size and power of the sector.</li>    <li>And today's news comes just two weeks after <a href=\"https://seekingalpha.com/news/3473873-twitter-facebook-dip-trump-comments\" target=\"_blank\">President Trump said</a> \"We should be suing Google and Facebook and perhaps we will\" in an interview with Fox Business.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476593\" data-linked=\"Apple, Amazon, Facebook, Google set to testify in House panel hearing\" data-tweet=\"$GOOG $GOOGL $AAPL - Apple, Amazon, Facebook, Google set to testify in House panel hearing https://seekingalpha.com/news/3476593-apple-amazon-facebook-google-set-to-testify-in-house-panel-hearing?source=tweet\" data-url=\"https://seekingalpha.com/news/3476593-apple-amazon-facebook-google-set-to-testify-in-house-panel-hearing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476591\" data-ts=\"1562695769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476591-optimism-over-new-gpu-products-prompts-apc-stock-target-hike-instinet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Optimism over new GPU products prompts APC stock target hike at Instinet</a></h4><ul><li>Advanced Micro Devices (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color=\"green\">+2.6%</font>) climbs to within a dollar of its 52-week high after Nomura <a href=\"https://www.marketwatch.com/story/amd-target-hiked-at-instinet-on-optimism-over-new-gpu-product-launches-2019-07-09\" target=\"_blank\">raised its price target</a> on the stock to $37 from $33 based on optimism over AMD's new Ryzen  desktop processing units.</li><li>Nomura analyst David Wong says the new units will help AMD sustain its desktop processor market share momentum and could drive unit market share to 20% by Q4 2019.</li><li>Wong expects AMD \"will be able to hold its desktop processor ASP at close to $90 or higher through 2019, up from close to $50 prior to 2017,\" and says he has growing confidence in the company's ability to continue gaining share due to a recent track record of strong execution.</li><li>AMD's average <a href=\"https://seekingalpha.com/symbol/AMD/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform and its <a href=\"https://seekingalpha.com/symbol/AMD/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Bullish, while its <a href=\"https://seekingalpha.com/symbol/AMD/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476591\" data-linked=\"Optimism over new GPU products prompts APC stock target hike at Instinet\" data-tweet=\"$AMD - Optimism over new GPU products prompts APC stock target hike at Instinet https://seekingalpha.com/news/3476591-optimism-over-new-gpu-products-prompts-apc-stock-target-hike-instinet?source=tweet\" data-url=\"https://seekingalpha.com/news/3476591-optimism-over-new-gpu-products-prompts-apc-stock-target-hike-instinet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476586\" data-ts=\"1562695283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476586-yuma-energy-and-eldorado-gold-among-energy-materials-gainers-liberty-oilfield-services-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yuma Energy and Eldorado Gold among Energy/Materials gainers; Liberty Oilfield Services and Mammoth Energy Services among losers</a></h4><ul><li><b>Gainers: </b>Yuma Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>) <font color=\"green\">+11%</font>. Eldorado Gold (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Liberty Oilfield Services (NYSE:<a href='https://seekingalpha.com/symbol/LBRT' title='Liberty Oilfield Services Inc.'>LBRT</a>) <font color=\"red\">-9%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"red\">-8%</font>. Rayonier Advanced Materials (NYSE:<a href='https://seekingalpha.com/symbol/RYAM' title='Rayonier Advanced Materials Inc.'>RYAM</a>) <font color=\"red\">-8%</font>. Superior Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a>) <font color=\"red\">-7%</font>. NOW (NYSE:<a href='https://seekingalpha.com/symbol/DNOW' title='NOW Inc.'>DNOW</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476586\" data-linked=\"Yuma Energy and Eldorado Gold among Energy/Materials gainers; Liberty Oilfield Services and Mammoth Energy Services among losers\" data-tweet=\"$YUMA $EGO $LBRT - Yuma Energy and Eldorado Gold among Energy/Materials gainers; Liberty Oilfield Services and Mammoth Energy Services among losers https://seekingalpha.com/news/3476586-yuma-energy-and-eldorado-gold-among-energy-materials-gainers-liberty-oilfield-services-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3476586-yuma-energy-and-eldorado-gold-among-energy-materials-gainers-liberty-oilfield-services-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476575\" data-ts=\"1562691732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476575-aqua-metals-leads-industrial-gainers-nuverra-environmental-solutions-and-american\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aqua Metals leads industrial gainers; Nuverra Environmental Solutions and American Superconductor among losers</a></h4><ul><li><b>Gainers: </b>Aqua Metals (NASDAQ:<a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals, Inc.'>AQMS</a>) <font color=\"green\">+11%</font>. Lindsay (NYSE:<a href='https://seekingalpha.com/symbol/LNN' title='Lindsay Corporation'>LNN</a>) <font color=\"green\">+9%</font>. ClearSign Combustion (NASDAQ:<a href='https://seekingalpha.com/symbol/CLIR' title='ClearSign Combustion Corporation'>CLIR</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>ReTo Eco-Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/RETO' title='ReTo Eco-Solutions, Inc.'>RETO</a>) <font color=\"red\">-11%</font>. Coda Octopus Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CODA' title='Coda Octopus Group, Inc.'>CODA</a>) <font color=\"red\">-9%</font>. American Superconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/AMSC' title='American Superconductor Corporation'>AMSC</a>) <font color=\"red\">-8%</font>. Nuverra Environmental Solutions (NYSEMKT:<a href='https://seekingalpha.com/symbol/NES' title='Nuverra Environmental Solutions, Inc.'>NES</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476575\" data-linked=\"Aqua Metals leads industrial gainers; Nuverra Environmental Solutions and American Superconductor among losers\" data-tweet=\"$AQMS $LNN $CLIR - Aqua Metals leads industrial gainers; Nuverra Environmental Solutions and American Superconductor among losers https://seekingalpha.com/news/3476575-aqua-metals-leads-industrial-gainers-nuverra-environmental-solutions-and-american?source=tweet\" data-url=\"https://seekingalpha.com/news/3476575-aqua-metals-leads-industrial-gainers-nuverra-environmental-solutions-and-american\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476574\" data-ts=\"1562691645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476574-consumers-in-u-s-continue-to-part\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumers in the U.S. continue to do their part</a></h4><ul> <li>Two solid <a href=\"https://www.cnbc.com/2019/07/09/pepsico-cfo-says-no-sign-of-a-consumer-slowdown-in-the-us.html\" target=\"_blank\">reads</a> on consumer spending arrived in today from the corporate world.</li> <li>PepsiCo (<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo, Inc.'>PEP</a> <font color='red'>-1.1%</font>) CFO Hugh Johnson said the food and beverage giant doesn't see any sign of a consumer slowdown, while General Mills (<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a> <font color='red'>-0.8%</font>) CEO Jeff Harmening called the consumer environment quite good.</li> <li>Solid employment trends and low gas prices are attributed as helping to keep U.S. consumer spending percolating even as the multinationals like PepsiCo and General Mills face pressure on the cost side of the equation.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476574\" data-linked=\"Consumers in the U.S. continue to do their part\" data-tweet=\"$PEP $GIS - Consumers in the U.S. continue to do their part https://seekingalpha.com/news/3476574-consumers-in-u-s-continue-to-part?source=tweet\" data-url=\"https://seekingalpha.com/news/3476574-consumers-in-u-s-continue-to-part\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476573\" data-ts=\"1562691594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476573-lendingclub-leads-financial-gainers-atif-holdings-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingClub leads financial gainers, ATIF Holdings among losers</a></h4><ul><li><b>Gainers:</b> LendingClub (NYSE:<a href='https://seekingalpha.com/symbol/LC' title='LendingClub Corporation'>LC</a>) <font color=\"green\">+7%</font>. Loop Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a>) <font color=\"green\">+6%</font>. Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> Manhattan Bridge Capital (NASDAQ:<a href='https://seekingalpha.com/symbol/LOAN' title='Manhattan Bridge Capital, Inc.'>LOAN</a>) <font color=\"red\">-6%</font>. ATIF Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ATIF' title='ATIF Holdings Limited'>ATIF</a>) <font color=\"red\">-5%</font>. U.S. Global Investors (NASDAQ:<a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476573\" data-linked=\"LendingClub leads financial gainers, ATIF Holdings among losers\" data-tweet=\"$LC $LOOP $YIN - LendingClub leads financial gainers, ATIF Holdings among losers https://seekingalpha.com/news/3476573-lendingclub-leads-financial-gainers-atif-holdings-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476573-lendingclub-leads-financial-gainers-atif-holdings-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476567\" data-ts=\"1562690653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476567-sage-therapeutics-up-5-stifel-touts-pipeline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage Therapeutics up 5% as Stifel touts pipeline</a></h4><ul><li>Stifel is bullish (BUY/$240) on Sage Therapeutics (<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a> <font color=\"green\">+4.8%</font>) based on its pipeline prospects.</li><li>A key future data readout is lead drug SAGE-217 in major depressive disorder. Other indications in development include bipolar depression, postpartum depression and insomnia.</li><li>Candidate #2, SAGE-324, is its Phase 1-stage program for Parkinson's, essential tremor and epileptiform disorders.</li><li>The just-started commercial launch of Zulresso (brexanolone) should, no doubt, contribute to Stifel's rosy outlook.</li><li>Sage is scheduled deliver another pipeline update on July 24.</li><li>SA Authors rating is <a href=\"https://seekingalpha.com/symbol/SAGE/ratings/author-ratings#filter=all\" target=\"_blank\">Bullish</a> while the Quant rating is <a href=\"https://seekingalpha.com/symbol/SAGE/ratings/quant-ratings\" target=\"_blank\">Neutral</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476567\" data-linked=\"Sage Therapeutics up 5% as Stifel touts pipeline\" data-tweet=\"$SAGE - Sage Therapeutics up 5% as Stifel touts pipeline https://seekingalpha.com/news/3476567-sage-therapeutics-up-5-stifel-touts-pipeline?source=tweet\" data-url=\"https://seekingalpha.com/news/3476567-sage-therapeutics-up-5-stifel-touts-pipeline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476566\" data-ts=\"1562690603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476566-acia-jfin-and-waas-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ACIA, JFIN and WAAS among midday movers</a></h4><ul><li><strong>Gainers: </strong>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+107%</font>. Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications, Inc.'>ACIA</a>) <font color=\"green\">+35%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+26%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+16%</font>. iFresh Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/IFMK' title='iFresh Inc.'>IFMK</a>) <font color=\"green\">+15%</font>. Atreca (NASDAQ:<a href='https://seekingalpha.com/symbol/BCEL' title='Atreca, Inc.'>BCEL</a>) <font color=\"green\">+15%</font>. Pareteum Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"green\">+14%</font>. Aclaris Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics, Inc.'>ACRS</a>) <font color=\"green\">+13%</font>. Resonant (NASDAQ:<a href='https://seekingalpha.com/symbol/RESN' title='Resonant Inc.'>RESN</a>) <font color=\"green\">+13%</font>. TransAct Technologies Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/TACT' title='TransAct Technologies Incorporated'>TACT</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>Jiayin Group (NASDAQ:<a href='https://seekingalpha.com/symbol/JFIN' title='Jiayin Group Inc.'>JFIN</a>) <font color=\"red\">-14%</font>. ReTo Eco-Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/RETO' title='ReTo Eco-Solutions, Inc.'>RETO</a>) <font color=\"red\">-12%</font>. Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"red\">-10%</font>. Immutep (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited'>IMMP</a>) <font color=\"red\">-10%</font>. AquaVenture Holdings (NYSE:<a href='https://seekingalpha.com/symbol/WAAS' title='AquaVenture Holdings Limited'>WAAS</a>) <font color=\"red\">-10%</font>. DGSE Companies (NYSEMKT:<a href='https://seekingalpha.com/symbol/DGSE' title='DGSE Companies, Inc.'>DGSE</a>) <font color=\"red\">-10%</font>. Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-10%</font>. Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) <font color=\"red\">-9%</font>. aTyr Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma, Inc.'>LIFE</a>) <font color=\"red\">-9%</font>. AgeX Therapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/AGE' title='AgeX Therapeutics, Inc.'>AGE</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476566\" data-linked=\"ACIA, JFIN and WAAS among midday movers\" data-tweet=\"$CEI $ACIA $SOLO - ACIA, JFIN and WAAS among midday movers https://seekingalpha.com/news/3476566-acia-jfin-and-waas-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476566-acia-jfin-and-waas-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476563\" data-ts=\"1562689971\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476563-california-senate-approves-bill-to-protect-utilities-from-wildfire-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">California Senate approves bill to protect utilities from wildfire costs</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+3.4%</font>) moves higher after California's state senate yesterday <a href=\"https://www.sfchronicle.com/business/article/California-lawmakers-advance-major-utility-14080228.php\" target=\"_blank\">easily passed legislation</a> to protect utilities from wildfire costs, with no amendments.</li><li>The bill, which would create a fund of at least $21B to cover future wildfire claims and launch several changes to the way the state oversees the safety of its electric grid, now heads to the state Assembly, which is under pressure from Gov. Newsom and Wall Street to act before the end of this week.</li><li>A key remaining issue is the ability of PG&amp;E to use net income securitization to finance wildfire damages and insurance fund contributions, as the bill contains no language that would enable this feature.</li><li>Southern California utilities Edison International (<a href='https://seekingalpha.com/symbol/EIX' title='Edison International'>EIX</a> <font color='red'>-0.1%</font>) and Sempra Energy (<a href='https://seekingalpha.com/symbol/SRE' title='Sempra Energy'>SRE</a>) are little changed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476563\" data-linked=\"California Senate approves bill to protect utilities from wildfire costs\" data-tweet=\"$PCG $EIX $SRE - California Senate approves bill to protect utilities from wildfire costs https://seekingalpha.com/news/3476563-california-senate-approves-bill-to-protect-utilities-from-wildfire-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3476563-california-senate-approves-bill-to-protect-utilities-from-wildfire-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476558\" data-ts=\"1562688363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CG\" target=\"_blank\">CG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476558-carlyle-groupplus-2_2-citi-adds-to-positive-catalyst-watch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carlyle Group +2.2% as Citi adds to positive catalyst watch</a></h4><ul><li>Carlyle Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group L.P.'>CG</a>) <font color=\"green\">gains 2.2%</font> after Citigroup analyst William Katz adds the firm to a \"30-day positive catalyst watch,\" saying it's likely Carlyle will announce it's converting to a c-corp when it reports earnings.</li><li>Keeps Och-Ziff Capital Management (<a href='https://seekingalpha.com/symbol/OZM' title='Och-Ziff Capital Management Group Inc.'>OZM</a> <font color='red'>-2.3%</font>) as a top pick among alternative asset managers on \"growing signs of a franchise upturn.\"</li><li>Shifts Blackstone Group (<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group Inc.'>BX</a> <font color='red'>-0.5%</font>) \"to the back of a pack\" after a recent rally limits remaining upside.</li><li>Among traditional asset managers, Katz remains most bullish on AllianceBernstein (<a href='https://seekingalpha.com/symbol/AB' title='AllianceBernstein Holding L.P.'>AB</a> <font color='green'>+0.2%</font>) and Legg Mason (<a href='https://seekingalpha.com/symbol/LM' title='Legg Mason, Inc.'>LM</a> <font color='green'>+0.6%</font>).</li><li>Carlyle Group quant rating<a href=\"https://seekingalpha.com/symbol/CG/ratings/quant-ratings?s=cg\" target=\"_blank\"> Neutral</a>; Och-Ziff quant rating <a href=\"https://seekingalpha.com/symbol/OZM/ratings/quant-ratings?s=ozm\" target=\"_blank\">Very Bullish</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476558\" data-linked=\"Carlyle Group +2.2% as Citi adds to positive catalyst watch\" data-tweet=\"$CG $OZM $BX - Carlyle Group +2.2% as Citi adds to positive catalyst watch https://seekingalpha.com/news/3476558-carlyle-groupplus-2_2-citi-adds-to-positive-catalyst-watch?source=tweet\" data-url=\"https://seekingalpha.com/news/3476558-carlyle-groupplus-2_2-citi-adds-to-positive-catalyst-watch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476556\" data-ts=\"1562688291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476556-e-l-f-beauty-and-nio-among-consumer-gainers-tenneco-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">e.l.f. Beauty and NIO among consumer gainers; Tenneco leads the losers</a></h4><ul><li><b>Gainers: </b>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+29%</font>. Ever-Glory International (NASDAQ:<a href='https://seekingalpha.com/symbol/EVK' title='Ever-Glory International Group, Inc.'>EVK</a>) <font color=\"green\">+19%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Inc.'>NIO</a>) <font color=\"green\">+10%</font>. Arcimoto (NASDAQ:<a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a>) <font color=\"green\">+8%</font>. e.l.f. Beauty (NYSE:<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty, Inc.'>ELF</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Tenneco (NYSE:<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a>) <font color=\"red\">-7%</font>. Garrett Motion (NYSE:<a href='https://seekingalpha.com/symbol/GTX' title='Garrett Motion Inc.'>GTX</a>) <font color=\"red\">-6%</font>. Verso (NYSE:<a href='https://seekingalpha.com/symbol/VRS' title='Verso Corporation'>VRS</a>) <font color=\"red\">-5%</font>. Clearwater Paper (NYSE:<a href='https://seekingalpha.com/symbol/CLW' title='Clearwater Paper Corporation'>CLW</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476556\" data-linked=\"e.l.f. Beauty and NIO among consumer gainers; Tenneco leads the losers\" data-tweet=\"$SOLO $EVK $NIO - e.l.f. Beauty and NIO among consumer gainers; Tenneco leads the losers https://seekingalpha.com/news/3476556-e-l-f-beauty-and-nio-among-consumer-gainers-tenneco-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476556-e-l-f-beauty-and-nio-among-consumer-gainers-tenneco-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476550\" data-ts=\"1562687798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476550-pulmatrix-up-4-on-advancement-of-mid-stage-pulmazole-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix up 4% on advancement of mid-stage Pulmazole study</a></h4><ul><li>Nano cap Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color=\"green\">+4.4%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17566314-pulmatrix-activates-sites-pulmazole-phase-2-clinical-study\" target=\"_blank\">announcement </a>that three sites in the U.S. have been activated for its <a href=\"https://clinicaltrials.gov/ct2/show/NCT03960606?lead=pulmatrix&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 study</a> of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis in asthma patients.</li><li>17 of the 25 treatment sites are in the U.S., UK and Australia. The remaining eight are in India and Poland.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476550\" data-linked=\"Pulmatrix up 4% on advancement of mid-stage Pulmazole study\" data-tweet=\"$PULM - Pulmatrix up 4% on advancement of mid-stage Pulmazole study https://seekingalpha.com/news/3476550-pulmatrix-up-4-on-advancement-of-mid-stage-pulmazole-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3476550-pulmatrix-up-4-on-advancement-of-mid-stage-pulmazole-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476547\" data-ts=\"1562687044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAYRY\" target=\"_blank\">BAYRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476547-bayer-approached-elanco-possible-deal-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bayer approached Elanco about possible deal - Bloomberg</a></h4><ul><li>Bloomberg reports that Bayer (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a> <font color=\"green\">+1.4%</font>) recently contacted Elanco Animal Health (<a href='https://seekingalpha.com/symbol/ELAN' title='Elanco Animal Health Incorporated'>ELAN</a> <font color=\"green\">+2.1%</font>) about a possible deal.</li><li>Bayer's animal health unit generated \u20ac421M (+1.7%) in sales in Q1, representing 3.2% of the company's overall revenues.</li><li>Elanco, spun out of Eli Lilly last year, generated $731M in sales in Q1.</li><li><strong>Update</strong>: According to the <a href=\"https://business.financialpost.com/pmn/business-pmn/germanys-bayer-seeks-animal-health-merger-with-elanco-sources\" target=\"_blank\">Financial Post</a>, the companies are discussing a merger. Bayer's motivation is raising cash after its $63B takeout of Monsanto.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476547\" data-linked=\"Bayer approached Elanco about possible deal - Bloomberg\" data-tweet=\"$BAYRY $ELAN - Bayer approached Elanco about possible deal - Bloomberg https://seekingalpha.com/news/3476547-bayer-approached-elanco-possible-deal-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3476547-bayer-approached-elanco-possible-deal-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476542\" data-ts=\"1562686625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TACT\" target=\"_blank\">TACT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476542-transact-announces-new-order-for-boha-hardware-and-software-solutions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransAct announces new order for BOHA! hardware and software solutions</a></h4><ul><li>TransAct Technologies (<a href='https://seekingalpha.com/symbol/TACT' title='TransAct Technologies Incorporated'>TACT</a> <font color=\"green\">+7.7%</font>) has <a href=\"https://seekingalpha.com/pr/17565804-transact-secures-new-order-boha-hardware-software-solutions-large-u-s-foodservice-provider\" target=\"_blank\">secured</a> a new agreement with a large U.S. foodservice provider for the deployment of the BOHA! hardware and one of the BOHA! SaaS-based apps at more than 400 locations by 2021-year end.</li><li>TransAct believes the annual recurring average revenue per location for this agreement will be ~$1,100.</li><li>The Company expects ~175 customer locations will be live with the BOHA! hardware and software solutions by 2019-year end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476542\" data-linked=\"TransAct announces new order for BOHA! hardware and software solutions\" data-tweet=\"$TACT - TransAct announces new order for BOHA! hardware and software solutions https://seekingalpha.com/news/3476542-transact-announces-new-order-for-boha-hardware-and-software-solutions?source=tweet\" data-url=\"https://seekingalpha.com/news/3476542-transact-announces-new-order-for-boha-hardware-and-software-solutions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476541\" data-ts=\"1562686368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476541-stranger-things-3-sets-netflix-record\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stranger Things 3 sets Netflix record</a></h4><ul> <li>Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+1.6%</font>) gains after tweeting late yesterday that <a href=\"https://twitter.com/netflix/status/1148359444188712960\" target=\"_blank\">40.7M</a> households have watched Stranger Things 3 since July 4 and over 18M have finished the entire season.</li> <li>The series set a Netflix streaming record over the four-day period.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476541\" data-linked=\"Stranger Things 3 sets Netflix record\" data-tweet=\"$NFLX - Stranger Things 3 sets Netflix record https://seekingalpha.com/news/3476541-stranger-things-3-sets-netflix-record?source=tweet\" data-url=\"https://seekingalpha.com/news/3476541-stranger-things-3-sets-netflix-record\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476534\" data-ts=\"1562685614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIB\" target=\"_blank\">BIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476534-drug-makers-perk-up-on-block-of-price-disclosures-in-tv-ads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drug makers perk up on block of price disclosures in TV ads</a></h4><ul><li>Biotechs and biopharma players are modestly in the green after a D.C. district court <a href=\"https://seekingalpha.com/news/3476378-rule-requiring-drug-prices-tv-ads-blocked\" target=\"_blank\">stopped </a>a Trump administration initiative requiring drug makers to disclose list prices in television advertisements.</li><li>Judge Amit Mehta <a href=\"https://www.npr.org/2019/07/09/739770699/judge-blocks-trump-rule-requiring-pharma-companies-to-say-price-of-drugs-in-tv-a\" target=\"_blank\">found </a>that the U.S. Department of Health and Human Services &#40;HHS&#41; lacks the regulatory authority to make drug firms include pricing information in TV ads.</li><li>Critics say the rule, if implemented, would not have made a material impact on pricing anyway since there was no enforcement mechanism for scofflaws. The assumption was that the private sector would police itself.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a>, <a href='https://seekingalpha.com/symbol/GRX' title='The Gabelli Healthcare & Wellness Rx Trust'>GRX</a>, <a href='https://seekingalpha.com/symbol/THW' title='Tekla World Healthcare Fund'>THW</a>, <a href='https://seekingalpha.com/symbol/BME' title='BlackRock Health Sciences Trust'>BME</a>, <a href='https://seekingalpha.com/symbol/BIS' title='ProShares UltraShort Nasdaq Biotechnology ETF'>BIS</a>, <a href='https://seekingalpha.com/symbol/IXJ' title='iShares Global Healthcare ETF'>IXJ</a>, <a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a>, <a href='https://seekingalpha.com/symbol/CHNA' title='The Loncar China BioPharma ETF'>CHNA</a>, <a href='https://seekingalpha.com/symbol/IDNA' title='iShares Genomics Immunology and Healthcare ETF'>IDNA</a>, <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a></li><li>Selected tickers: Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"green\">+0.8%</font>), Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"green\">+1.3%</font>), Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"green\">+0.8%</font>), Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"green\">+1.1%</font>), Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color=\"green\">+0.8%</font>), Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color=\"green\">+0.4%</font>), AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a>), GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a> <font color=\"green\">+1%</font>), Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"green\">+0.2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476534\" data-linked=\"Drug makers perk up on block of price disclosures in TV ads\" data-tweet=\"$BIB $GRX $THW - Drug makers perk up on block of price disclosures in TV ads https://seekingalpha.com/news/3476534-drug-makers-perk-up-on-block-of-price-disclosures-in-tv-ads?source=tweet\" data-url=\"https://seekingalpha.com/news/3476534-drug-makers-perk-up-on-block-of-price-disclosures-in-tv-ads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476533\" data-ts=\"1562685252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MFGP\" target=\"_blank\">MFGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476533-micro-focusminus-5_9-after-h1-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micro Focus -5.9% after H1 revenue miss</a></h4><ul><li>Micro Focus International (NYSE:<a href='https://seekingalpha.com/symbol/MFGP' title='Micro Focus International plc'>MFGP</a>) <font color=\"red\">slumps 5.9%</font> after<a href=\"https://investors.microfocus.com/investors-media/results-reports/results-centre/\" target=\"_blank\"> H1 revenue </a>of $1.66B fell 5.3% Y/Y, missing the $1.69B Capital IQ consensus.</li><li>H1 adjusted EPS from continuing operations of 86 cents improved from 79 cents in the year-ago period.</li><li>H1 statutory loss from continuing operations was $78.3M vs. profit of $600.0M in the year-ago period.</li><li>Adjusted EBITDA of $662.3M vs. $650.4M on constant currency basis; adjusted EBITDA margin of 40.0% vs. 37.2% in FY2018, driven mostly by continued cost management actions related to the HPE software integration program.</li><li>Announces interim dividend of 58.33 cents per share.</li><li>Reiterates guidance for constant currency revenue declining 4%-6% for the fiscal year ending Oct. 31, 2019 vs the previous fiscal year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3476392-micro-focus-reports-1h-results\" target=\"_blank\">Micro Focus reports 1H results</a> (July 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476533\" data-linked=\"Micro Focus -5.9% after H1 revenue miss\" data-tweet=\"$MFGP - Micro Focus -5.9% after H1 revenue miss https://seekingalpha.com/news/3476533-micro-focusminus-5_9-after-h1-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3476533-micro-focusminus-5_9-after-h1-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476532\" data-ts=\"1562685239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELF\" target=\"_blank\">ELF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476532-jpmorgan-turns-positive-on-e-l-f-beauty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan turns positive on e.l.f. Beauty</a></h4><ul> <li>JPMorgan lifts e.l.f. Beauty (<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty, Inc.'>ELF</a> <font color='green'>+8%</font>) to an Overweight rating after having it slotted at Neutral.</li> <li>The firm assigns a price target of $17 to ELF vs. the <a href=\"https://seekingalpha.com/symbol/ELF/ratings/sell-side-ratings\" target=\"_blank\">sell-side average PT</a> of $11.30 and the 52-week high of $16.82.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476532\" data-linked=\"JPMorgan turns positive on e.l.f. Beauty\" data-tweet=\"$ELF - JPMorgan turns positive on e.l.f. Beauty https://seekingalpha.com/news/3476532-jpmorgan-turns-positive-on-e-l-f-beauty?source=tweet\" data-url=\"https://seekingalpha.com/news/3476532-jpmorgan-turns-positive-on-e-l-f-beauty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476529\" data-ts=\"1562684831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476529-adamis-pharmaceuticals-and-aac-holdings-among-healthcare-gainers-karyopharm-therapeutics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis Pharmaceuticals and AAC Holdings among healthcare gainers; Karyopharm Therapeutics leads the losers</a></h4><ul><li><b>Gainers: </b>AAC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AAC' title='AAC Holdings, Inc.'>AAC</a>) <font color=\"green\">+18%</font>. Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+15%</font>. Adamis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) <font color=\"green\">+9%</font>. CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics, Inc.'>CTMX</a>) <font color=\"green\">+8%</font>. Oasmia Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical AB &#40;publ&#41;'>OASM</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Karyopharm Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KPTI' title='Karyopharm Therapeutics Inc.'>KPTI</a>) <font color=\"red\">-9%</font>. Immutep (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited'>IMMP</a>) <font color=\"red\">-9%</font>. Avinger (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger, Inc.'>AVGR</a>) <font color=\"red\">-8%</font>. Corindus Vascular Robotics (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVRS' title='Corindus Vascular Robotics, Inc.'>CVRS</a>) <font color=\"red\">-8%</font>. Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476529\" data-linked=\"Adamis Pharmaceuticals and AAC Holdings among healthcare gainers; Karyopharm Therapeutics leads the losers\" data-tweet=\"$AAC $XBIO $ADMP - Adamis Pharmaceuticals and AAC Holdings among healthcare gainers; Karyopharm Therapeutics leads the losers https://seekingalpha.com/news/3476529-adamis-pharmaceuticals-and-aac-holdings-among-healthcare-gainers-karyopharm-therapeutics?source=tweet\" data-url=\"https://seekingalpha.com/news/3476529-adamis-pharmaceuticals-and-aac-holdings-among-healthcare-gainers-karyopharm-therapeutics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476519\" data-ts=\"1562683312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476519-square-short-thesis-mostly-played-out-raymond-james-says-in-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square short thesis mostly played out, Raymond James says in upgrade</a></h4><ul><li>Square (<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a> <font color='green'>+5.6%</font>) surges after Raymond James <a href=\"https://www.marketwatch.com/story/square-stock-gains-after-raymond-james-ends-bearish-call-2019-07-09\" target=\"_blank\">upgrades</a> shares to Market Perform from Underperform, as analyst John Davis says his short thesis from late January has mostly played out and the stock's risk-reward profile has become more balanced.</li><li>Davis says he had \"concerns that the magnitude of the top-line beats would likely wane, and more importantly, the deceleration in 2Q19 organic growth could catch some investors by surprise, [but] following the company's smallest revenue beat in recent memory in 1Q (+$7 million above top end of guide), a 2Q guide that came in below expectations, and a now well-telegraphed margin cadence (~+200 bp), the negative catalysts have mostly played out and the stock has lagged peers.\"</li><li>The analyst, who believes the stock remains expensive, also thinks SQ's business-to-business seller card is \"gaining traction\" and could provide enough momentum to exceed expectations in H2 2019.</li><li>Argus <a href=\"https://seekingalpha.com/news/3476174-argus-sees-upside-square\" target=\"_blank\">said yesterday</a> it started coverage of the stock with a Buy rating.</li><li>SQ's Seeking Alpha Authors Rating and Quant Rating are both Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476519\" data-linked=\"Square short thesis mostly played out, Raymond James says in upgrade\" data-tweet=\"$SQ - Square short thesis mostly played out, Raymond James says in upgrade https://seekingalpha.com/news/3476519-square-short-thesis-mostly-played-out-raymond-james-says-in-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3476519-square-short-thesis-mostly-played-out-raymond-james-says-in-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476513\" data-ts=\"1562682369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UEEC\" target=\"_blank\">UEEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476513-uhp-up-1-on-hemostyp-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UHP up 1% on HemoStyp update</a></h4><ul><li>Thinly traded micro cap United Health Products (<a href='https://seekingalpha.com/symbol/UEEC' title='United Health Products, Inc.'>OTCPK:UEEC</a> <font color=\"green\">+1%</font>) perks up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17565924-united-health-products-issues-shareholder-update\" target=\"_blank\">update</a> on hemostatic gauze <a href=\"https://www.unitedhealthproductsinc.com/medical-products\" target=\"_blank\">HemoStyp</a>.</li><li>A study evaluating HemoStyp in a surgical setting is ongoing, aimed at supporting a U.S. 510(k) marketing application as a Class III product. Enrollment should wind up in the next week or two.</li><li>The company is also conducting a preclinical study assessing HemoStyp's effects on bone. If positive, a human trial will be next up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476513\" data-linked=\"UHP up 1% on HemoStyp update\" data-tweet=\"$UEEC - UHP up 1% on HemoStyp update https://seekingalpha.com/news/3476513-uhp-up-1-on-hemostyp-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3476513-uhp-up-1-on-hemostyp-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476514\" data-ts=\"1562682332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476514-lululemonminus-1-after-d-davidson-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon -1% after D.A. Davidson warning</a></h4><ul> <li>D.A. Davidson thinks Lululemon (<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color='red'>-1%</font>) may have maxed out its pricing power as starts to see more promotions out of the company.</li> <li>The firm cuts its LULU price target to $175 from $190 on a lower full-year EPS forecast ($4.75 vs. $4.77 prior). The new PT is below the <a href=\"https://seekingalpha.com/symbol/LULU/ratings/sell-side-ratings\" target=\"_blank\">consensus sell-side mark</a> of $190.80.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476514\" data-linked=\"Lululemon -1% after D.A. Davidson warning\" data-tweet=\"$LULU - Lululemon -1% after D.A. Davidson warning https://seekingalpha.com/news/3476514-lululemonminus-1-after-d-davidson-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3476514-lululemonminus-1-after-d-davidson-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476504\" data-ts=\"1562681632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PURE\" target=\"_blank\">PURE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476504-pure-bio-up-13-on-profit-boosting-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PURE Bio up 13% on profit-boosting plan</a></h4><ul><li>Thinly traded nano cap PURE Bioscience (<a href='https://seekingalpha.com/symbol/PURE' title='PURE Bioscience, Inc.'>OTC:PURE</a> <font color=\"green\">+12.5%</font>) is up on a 4x surge in volume, albeit on turnover of only 82K shares, following its announced <a href=\"https://seekingalpha.com/pr/17565730-pure-bioscience-announces-initiatives-accelerate-drive-toward-profitability-reduce-overhead\" target=\"_blank\">initiatives </a>to accelerate its path to profitability by Q4.</li><li>It will move its corporate headquarters to Rancho Cucamonga, CA where it will co-locate with Swabplus.</li><li>CEO Hank Lambert will retire on August 7 at which time Chairman Tom Lee will take over as CEO.</li><li>The company says the actions will reduce its breakeven cash flow to revenue run rate to $4.5M from $5.0M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476504\" data-linked=\"PURE Bio up 13% on profit-boosting plan\" data-tweet=\"$PURE - PURE Bio up 13% on profit-boosting plan https://seekingalpha.com/news/3476504-pure-bio-up-13-on-profit-boosting-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3476504-pure-bio-up-13-on-profit-boosting-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476499\" data-ts=\"1562680981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMCM\" target=\"_blank\">OMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476499-symbio-signs-agreement-for-omnicomm-s-trialmaster-edc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Symbio signs agreement for OmniComm\u2019s TrialMaster® EDC</a></h4><ul><li>Symbio LLC, a clinical research organization has <a href=\"https://seekingalpha.com/pr/17566069-symbio-signs-five-year-agreement-omnicomm-s-trialmaster-edc\" target=\"_blank\">signed a five-year contract</a> with (<a href='https://seekingalpha.com/symbol/OMCM' title='OmniComm Systems, Inc.'>OTCQX:OMCM</a>) OmniComm Systems.</li><li>Under the agreement, Symbio will use OmniComm\u2019s TrialMaster version 5 to develop and manage clinical study databases.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476499\" data-linked=\"Symbio signs agreement for OmniComm\u2019s TrialMaster® EDC\" data-tweet=\"$OMCM - Symbio signs agreement for OmniComm\u2019s TrialMaster® EDC https://seekingalpha.com/news/3476499-symbio-signs-agreement-for-omnicomm-s-trialmaster-edc?source=tweet\" data-url=\"https://seekingalpha.com/news/3476499-symbio-signs-agreement-for-omnicomm-s-trialmaster-edc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476496\" data-ts=\"1562680686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THS\" target=\"_blank\">THS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476496-treehouse-foods-seen-better-off-without-snacks-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TreeHouse Foods seen better off without snacks business</a></h4><ul> <li>TreeHouse Foods (<a href='https://seekingalpha.com/symbol/THS' title='TreeHouse Foods, Inc.'>THS</a> <font color='green'>+1.4%</font>) gains after announcing a deal to sell its snacks division.</li> <li>Analysts are generally favorable in the deal, with Stifel noting that the company is better off without snacks weighing it down and SunTrust saying the low deal price was only slightly below expectations.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3476310-treehouse-foods-unloads-snacks-division\" target=\"_blank\">TreeHouse Foods unloads snacks division</a> (July 8)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476496\" data-linked=\"TreeHouse Foods seen better off without snacks business\" data-tweet=\"$THS - TreeHouse Foods seen better off without snacks business https://seekingalpha.com/news/3476496-treehouse-foods-seen-better-off-without-snacks-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3476496-treehouse-foods-seen-better-off-without-snacks-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476492\" data-ts=\"1562680432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMP\" target=\"_blank\">IMMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476492-immutep-down-15-on-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immutep down 15% on capital raise</a></h4><ul><li>Thinly traded nano cap Immutep Limited (<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited'>IMMP</a> <font color=\"red\">-14.8%</font>) is down on a 45% jump in volume, albeit on turnover of only 45K shares, in reaction to its A$10M private <a href=\"https://seekingalpha.com/pr/17565570-immutep-raises-10-million-via-private-placement-underwritten-entitlement-offer\" target=\"_blank\">stock placement</a>.</li><li>Specifically, the offering was 190.5M ordinary shares at A$0.021 per share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476492\" data-linked=\"Immutep down 15% on capital raise\" data-tweet=\"$IMMP - Immutep down 15% on capital raise https://seekingalpha.com/news/3476492-immutep-down-15-on-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3476492-immutep-down-15-on-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476481\" data-ts=\"1562679019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476481-veonplus-2_4-amid-upgrade-to-buy-bofaml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veon +2.4% amid upgrade to Buy at BofAML</a></h4><ul>   <li>Veon (NASDAQ:<a href='https://seekingalpha.com/symbol/VEON' title='VEON Ltd.'>VEON</a>) is <font color=\"green\">up 2.4%</font> premarket after an upgrade to Buy at BofA Merrill Lynch, on a variety of positive catalysts.</li>    <li>Analyst Cesar Tiron points to operational stabilization in Russia and says the second half will benefit from easier comparisons. Meanwhile, technical factors might improve as Telenor (<a href='https://seekingalpha.com/symbol/TELNY' title='Telenor ASA'>OTCPK:TELNY</a>) is down to an 8.9% stake as it sheds its holdings, he writes.</li>    <li>A boosted price target of $3.80 implies 22% upside.</li>    <li>Sell-side analysts rate it <a href=\"https://seekingalpha.com/symbol/VEON/ratings/sell-side-ratings\" target=\"_blank\">Outperform on average</a>, while <a href=\"https://seekingalpha.com/symbol/VEON/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>. The stock has a <a href=\"https://seekingalpha.com/symbol/VEON/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bullish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476481\" data-linked=\"Veon +2.4% amid upgrade to Buy at BofAML\" data-tweet=\"$VEON $TELNY - Veon +2.4% amid upgrade to Buy at BofAML https://seekingalpha.com/news/3476481-veonplus-2_4-amid-upgrade-to-buy-bofaml?source=tweet\" data-url=\"https://seekingalpha.com/news/3476481-veonplus-2_4-amid-upgrade-to-buy-bofaml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476478\" data-ts=\"1562678659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476478-sarepta-up-2-premarket-ms-boosts-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta up 2% premarket as MS boosts target</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) perks up <font color=\"green\">2%</font> premarket on light volume on the heels of Morgan Stanley's revision of its fair value target to $220 (50% upside) from $165 citing increased confidence that the company will capture the majority of market share in DMD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476478\" data-linked=\"Sarepta up 2% premarket as MS boosts target\" data-tweet=\"$SRPT - Sarepta up 2% premarket as MS boosts target https://seekingalpha.com/news/3476478-sarepta-up-2-premarket-ms-boosts-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3476478-sarepta-up-2-premarket-ms-boosts-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476473\" data-ts=\"1562678363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476473-m-dominate-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">M&amp;A dominate premarket gainers</a></h4><ul><li>Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications, Inc.'>ACIA</a>) <font color=\"green\">+37%</font> on <a href=\"https://seekingalpha.com/news/3476440-cisco-buy-supplier-acacia-2_6b\" target=\"_blank\">being acquired</a> by Cisco.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+30%</font> on the <a href=\"https://seekingalpha.com/pr/17565619-camber-energy-inc-announces-acquisition-lineal-star-holdings\" target=\"_blank\">acquisition</a> of Lineal Star Holdings, LLC.</li><li>Check-Cap (NASDAQ:<a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a>) <font color=\"green\">+17%</font> as C-Scan <a href=\"https://seekingalpha.com/news/3476407-check-caps-c-scan-beats-reference-test-study-shares-20-percent-premarket\" target=\"_blank\">beats reference test</a> in study.</li><li>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+12%</font> after attracting a <a href=\"https://seekingalpha.com/news/3476458-electameccanica-vehicles-plus-15-percent-attracting-bull-rating\" target=\"_blank\">bull rating</a>.</li><li>Titan Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/pr/17565846-titan-pharmaceuticals-expands-patient-access-probuphine-via-specialty-product-distribution\" target=\"_blank\">expanding</a> access to treatment with Probuphine implant, Titan's novel maintenance treatment for Opioid Use Disorder in eligible patients.</li><li>Adamis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/pr/17565697-adamis-pharmaceuticals-provides-update-u-s-retail-launch-symjepi\" target=\"_blank\">update</a> on U.S. retail launch of SYMJEPI.</li><li>Oasmia Pharmaceutical AB (NASDAQ:<a href='https://seekingalpha.com/symbol/OASM' title='Oasmia Pharmaceutical AB &#40;publ&#41;'>OASM</a>) <font color=\"green\">+10%</font>.</li><li>Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3476410-altimmune-10-percent-premarket-acquisition-spitfire-pharma\" target=\"_blank\">acquisition</a> of Spitfire Pharma.</li><li>NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3476456-ciscos-acacia-takeover-sends-optical-stocks-surging\" target=\"_blank\">Acacia acquisition news</a>.</li><li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3476456-ciscos-acacia-takeover-sends-optical-stocks-surging\" target=\"_blank\">Acacia acquisition news</a>.</li><li>Cellectar Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>) <font color=\"green\">+6%</font> as <a href=\"https://seekingalpha.com/news/3476463-cellectars-crl-131-fast-trackd-dlbcl-shares-6-percent-premarket\" target=\"_blank\">CRL 131 Fast Track'd</a> for DLBCL.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476473\" data-linked=\"M&amp;A dominate premarket gainers\" data-tweet=\"$ACIA $CEI $CHEK - M&amp;A dominate premarket gainers https://seekingalpha.com/news/3476473-m-dominate-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476473-m-dominate-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476471\" data-ts=\"1562678199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTNP\" target=\"_blank\">TTNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476471-titan-pharma-up-12-premarket-on-probuphine-distribution-deal-cvs-health\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan Pharma up 12% premarket on Probuphine distribution deal with CVS Health</a></h4><ul><li>Thinly traded nano cap Tital Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a>) is up <font color=\"green\">12% </font>premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17565846-titan-pharmaceuticals-expands-patient-access-probuphine-via-specialty-product-distribution\" target=\"_blank\">agreement </a>with CVS Health unit CVS Caremark for the distribution of its Probuphine (buprenorphine) implant for the treatment of opioid use disorder.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476471\" data-linked=\"Titan Pharma up 12% premarket on Probuphine distribution deal with CVS Health\" data-tweet=\"$TTNP - Titan Pharma up 12% premarket on Probuphine distribution deal with CVS Health https://seekingalpha.com/news/3476471-titan-pharma-up-12-premarket-on-probuphine-distribution-deal-cvs-health?source=tweet\" data-url=\"https://seekingalpha.com/news/3476471-titan-pharma-up-12-premarket-on-probuphine-distribution-deal-cvs-health\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476466\" data-ts=\"1562677562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476466-soly-noah-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SOLY, NOAH among premarket losers</a></h4><ul><li>Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"red\">-7%</font>.</li><li>Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476466\" data-linked=\"SOLY, NOAH among premarket losers\" data-tweet=\"$SOLY $NOAH - SOLY, NOAH among premarket losers https://seekingalpha.com/news/3476466-soly-noah-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3476466-soly-noah-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476463\" data-ts=\"1562677381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRB\" target=\"_blank\">CLRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476463-cellectars-crl-131-fast-trackd-for-dlbcl-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectar&#39;s CRL 131 Fast Track&#39;d for DLBCL; shares up 6% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17565703-cellectar-receives-fda-fast-track-designation-clr-131-diffuse-large-b-cell-lymphoma\" target=\"_blank\">designates </a>Cellectar Biosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>) lead candidate CLR 131 for Fast Track review for the treatment of relapsed/refractory diffuse large B-cell lymphoma &#40;DLBCL&#41;.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li>A Phase 2 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02952508?term=cellectar&amp;rank=2\" target=\"_blank\">CLOVER-1</a>, is in process. The estimated primary completion date is December.</li><li>CLR 131 is a phospholipid ether-drug conjugate &#40;PDC&#41; that selectively delivers radiation to malignant cancer cells.</li><li>Shares are up <font color=\"green\">6%</font> premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476463\" data-linked=\"Cellectar&#39;s CRL 131 Fast Track&#39;d for DLBCL; shares up 6% premarket\" data-tweet=\"$CLRB - Cellectar&#39;s CRL 131 Fast Track&#39;d for DLBCL; shares up 6% premarket https://seekingalpha.com/news/3476463-cellectars-crl-131-fast-trackd-for-dlbcl-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3476463-cellectars-crl-131-fast-trackd-for-dlbcl-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476459\" data-ts=\"1562677194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476459-trovagene-begins-patient-enrollment-in-early-stage-colorectal-cancer-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene begins patient enrollment in early-stage colorectal cancer trial</a></h4><ul><li>Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) has <a href=\"https://seekingalpha.com/pr/17565498-trovagene-announces-initiation-enrollment-phase-1b-2-clinical-trial-kras-mutated-colorectal\" target=\"_blank\">initiated</a> patient enrollment in its Phase 1b/2 study of <a href=\"https://trovageneoncology.com/onvansertib/\" target=\"_blank\">onvansertib</a> in combination with FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.</li><li>The trial will enroll up to 44 patients with a KRAS mutation and histologically confirmed metastatic and unresectable disease. In addition, patients must have failed treatment or be intolerant of FOLFOX (fluoropyrimidine and oxaliplatin) with or without Avastin (bevacizumab).</li><li>The trial is being conducted at three cancer centers: USC Norris Comprehensive Cancer Center, Hoag Cancer Center and The Mayo Clinic.</li><li>Trovagene licensed onvansertib (also known as NMS-1286937 and PCM-075) from Nerviano Medical Sciences.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476459\" data-linked=\"Trovagene begins patient enrollment in early-stage colorectal cancer trial\" data-tweet=\"$TROV - Trovagene begins patient enrollment in early-stage colorectal cancer trial https://seekingalpha.com/news/3476459-trovagene-begins-patient-enrollment-in-early-stage-colorectal-cancer-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3476459-trovagene-begins-patient-enrollment-in-early-stage-colorectal-cancer-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476458\" data-ts=\"1562677137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLO\" target=\"_blank\">SOLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476458-electameccanica-vehiclesplus-15-after-attracting-bull-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electameccanica Vehicles +15% after attracting a bull rating</a></h4><ul> <li>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) pops in early trading after Roth Capital steps in with a new Buy rating.</li> <li>The stock is thinly-covered on Wall Street, with only two firms on record with Buy-equivalent ratings.</li> <li>Last month, the electric minicar maker appointed Paul Rivera as its new CEO. Looking ahead, Electrameccanica Vehicles says it has more than 60K vehicle pre-orders and opened a production facility in Chongqing, China aimed at mass production.</li> <li>Shares of SOLO are <font color=\"green\">up 14.90%</font> premarket to $2.70 on volume of 61K vs. the 52-week trading range of $7.48 to $0.90.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476458\" data-linked=\"Electameccanica Vehicles +15% after attracting a bull rating\" data-tweet=\"$SOLO - Electameccanica Vehicles +15% after attracting a bull rating https://seekingalpha.com/news/3476458-electameccanica-vehiclesplus-15-after-attracting-bull-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3476458-electameccanica-vehiclesplus-15-after-attracting-bull-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476456\" data-ts=\"1562676494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NPTN\" target=\"_blank\">NPTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476456-ciscos-acacia-takeover-sends-optical-stocks-surging\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco&#39;s Acacia takeover sends optical stocks surging</a></h4><ul><li>Optical networking stocks are <a href=\"https://www.marketwatch.com/story/optical-networking-stocks-surge-after-ciscos-deal-to-buy-acacia-2019-07-09\" target=\"_blank\">on the move</a> after Cisco Systems <a href=\"https://seekingalpha.com/news/3476440-cisco-buy-supplier-acacia-2_6b\" target=\"_blank\">agrees to buy</a> Acacia Communications at a 46% premium to Monday's $48.06 closing price: <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color=\"green\">+8.6%</font>, <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color=\"green\">+7.4%</font>, <a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color=\"green\">+3.9%</font>, <a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a> <font color=\"green\">+3.2%</font>, <a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a> <font color=\"green\">+3.1%</font>, <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color=\"green\">+2.9%</font>.</li><li>The deal is CSCO's biggest acquisition since its $3.7B purchase of AppDynamics in 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476456\" data-linked=\"Cisco&#39;s Acacia takeover sends optical stocks surging\" data-tweet=\"$NPTN $AAOI $LITE - Cisco&#39;s Acacia takeover sends optical stocks surging https://seekingalpha.com/news/3476456-ciscos-acacia-takeover-sends-optical-stocks-surging?source=tweet\" data-url=\"https://seekingalpha.com/news/3476456-ciscos-acacia-takeover-sends-optical-stocks-surging\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476454\" data-ts=\"1562676326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMD\" target=\"_blank\">CRMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476454-cormedix-down-3-premarket-on-neutrolin-nda-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CorMedix down 3% premarket on Neutrolin NDA update</a></h4><ul><li>Citing FDA feedback, CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix, Inc.'>CRMD</a>) says it does not believe that it will be required to <a href=\"https://seekingalpha.com/pr/17565633-cormedix-receives-encouraging-fda-feedback-neutrolin-lockminus-100-data\" target=\"_blank\">conduct another Phase 3 study</a> evaluating Neutrolin as a catheter lock solution for the prevention of catheter-related bloodstream infections in hemodialysis patients.</li><li>The agency stated that results from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02651428?term=cormedix&amp;rank=3\" target=\"_blank\">LOCK-IT-100</a> trial may be sufficient to support a marketing application but deferred a final determination until after it has reviewed the NDA.</li><li>Discussions on chemistry, manufacturing and controls &#40;CMC&#41; data are ongoing. Once resolved, a pre-IND meeting will be next up.</li><li>Shares <a href=\"https://seekingalpha.com/news/3433466-cormedix-18-percent-cautious-statement-ceo-re-late-stage-neutrolin-data\" target=\"_blank\">sold off in February</a> on concerns that the FDA would require another Phase 3 study, still a possibility.</li><li>Shares are down <font color=\"red\">3%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476454\" data-linked=\"CorMedix down 3% premarket on Neutrolin NDA update\" data-tweet=\"$CRMD - CorMedix down 3% premarket on Neutrolin NDA update https://seekingalpha.com/news/3476454-cormedix-down-3-premarket-on-neutrolin-nda-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3476454-cormedix-down-3-premarket-on-neutrolin-nda-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476449\" data-ts=\"1562675771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476449-eyegate-to-start-obg-pilot-study-for-pe-shares-up-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyeGate to start OBG pilot study for PE; shares up 14% premarket</a></h4><ul> <li>EyeGate Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals, Inc.'>EYEG</a>) has <a href=\"https://seekingalpha.com/pr/17565303-eyegate-files-fda-submission-initiate-pe-pilot-study\" target=\"_blank\">filed</a> a protocol with the FDA for a follow-on pilot study using the Ocular Bandage Gel (\"OBG\") eye drop to treat punctate epitheliopathies (\"PE\") which can be associated with dry eye.</li><li>The FDA review process takes 30 days, where the agency will allow to initiate enrollment or will provide comments to be addressed.</li> <li>The objective of this study is to evaluate several different exploratory performance endpoints in PE patients.</li><li>Following data from this study, expected by year end 2019, EyeGate plans to meet with the FDA to discuss the results and confirm the most ideal endpoint to use in the pivotal study.</li> <li>The Company plans to have two clinical studies, expanding the uses for OBG.</li><li>Shares are up <font color=\"green\">14%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476449\" data-linked=\"EyeGate to start OBG pilot study for PE; shares up 14% premarket\" data-tweet=\"$EYEG - EyeGate to start OBG pilot study for PE; shares up 14% premarket https://seekingalpha.com/news/3476449-eyegate-to-start-obg-pilot-study-for-pe-shares-up-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3476449-eyegate-to-start-obg-pilot-study-for-pe-shares-up-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476445\" data-ts=\"1562675144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIX\" target=\"_blank\">SIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476445-wells-fargo-sees-sunny-days-for-six-flags\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo sees sunny days for Six Flags</a></h4><ul> <li>Wells Fargo upgrades Six Flags Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/SIX' title='Six Flags Entertainment Corporation'>SIX</a>) to an Outperform rating from Market Perform.</li> <li>Analyst Timothy Conder points to improving weather trends and expects upward Street revisions to China estimates and adjusted EBITDA.</li> <li>On a macro level, Conder notes the regional price/value \"getaway\" proposition offered to consumers by Six Flags parks in a slow growth U.S. economic environment.</li> <li>WF's price target of $56 implies a 12.0x EV/EBITDA multiple. The average sell-side PT is $59.17. The 52-week high is $72.39.</li> <li>Shares of Six Flags are <font color=\"green\">up 0.67%</font> premarket to $52.65.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476445\" data-linked=\"Wells Fargo sees sunny days for Six Flags\" data-tweet=\"$SIX - Wells Fargo sees sunny days for Six Flags https://seekingalpha.com/news/3476445-wells-fargo-sees-sunny-days-for-six-flags?source=tweet\" data-url=\"https://seekingalpha.com/news/3476445-wells-fargo-sees-sunny-days-for-six-flags\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476443\" data-ts=\"1562675010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VXRT\" target=\"_blank\">VXRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476443-vaxart-up-11-premarket-on-janssen-deal-for-oral-flu-vaccine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vaxart up 11% premarket on Janssen deal for oral flu vaccine</a></h4><ul><li>Nano cap Vaxart (NASDAQ:<a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a>) is up <font color=\"green\">11%</font> premarket on modest volume in reaction to its <a href=\"https://seekingalpha.com/pr/17565447-vaxart-enters-research-collaboration-janssen-evaluate-oral-universal-influenza-vaccine\" target=\"_blank\">research collaboration</a> with Johnson &amp; Johnson's (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) Janssen Vaccines &amp; Prevention B.V. to evaluate VXRT's oral vaccine platform for its universal influenza vaccine program.</li><li>Under the terms of the agreement, VXRT will produce an oral vaccine containing certain proprietary antigens from Janssen and will test the candidate in a preclinical challenge model. Once completed, Janssen will have the option to negotiate an exclusive global license to VXRT's technology encompassing these antigens.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476443\" data-linked=\"Vaxart up 11% premarket on Janssen deal for oral flu vaccine\" data-tweet=\"$VXRT $JNJ - Vaxart up 11% premarket on Janssen deal for oral flu vaccine https://seekingalpha.com/news/3476443-vaxart-up-11-premarket-on-janssen-deal-for-oral-flu-vaccine?source=tweet\" data-url=\"https://seekingalpha.com/news/3476443-vaxart-up-11-premarket-on-janssen-deal-for-oral-flu-vaccine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476440\" data-ts=\"1562674692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476440-cisco-to-buy-supplier-acacia-for-2_6b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco to buy supplier Acacia for $2.6B</a></h4><ul><li>Cisco (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) has agreed to <a href=\"https://seekingalpha.com/pr/17565526-cisco-intends-acquire-acacia-communications\" target=\"_blank\">acquire</a> one of its existing suppliers, Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications, Inc.'>ACIA</a>), to meet the fast-growing consumer demands for data.</li><li>\"With the explosion of bandwidth in the multi-cloud era, optical interconnect technologies are becoming increasingly strategic,\" said Cisco's David Goeckeler regarding the purchase.</li><li>Under the terms of the agreement, Cisco will pay $70 per Acacia share in cash, or for approximately $2.6B on a fully diluted basis, net of cash and marketable securities.</li><li>CSCO <font color=\"red\">-1%</font>; ACIA <font color=\"green\">+38.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3476440\" data-linked=\"Cisco to buy supplier Acacia for $2.6B\" data-tweet=\"$CSCO $ACIA - Cisco to buy supplier Acacia for $2.6B https://seekingalpha.com/news/3476440-cisco-to-buy-supplier-acacia-for-2_6b?source=tweet\" data-url=\"https://seekingalpha.com/news/3476440-cisco-to-buy-supplier-acacia-for-2_6b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476437\" data-ts=\"1562674320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBUX\" target=\"_blank\">SBUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476437-starbucks-adds-new-markets-to-delivery-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starbucks adds new markets to delivery program</a></h4><ul> <li>Starbucks (NASDAQ:<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a>) has added Dallas, Houston and Orange County to its Starbucks Delivers program powered by Uber Eats, according to Bloomberg.</li> <li>Starbucks Delivers is also available in Boston, Chicago, Los Angeles, Miami, New York City, San Francisco Bay area, Seattle and the Washington, D.C area.</li> <li>The program features delivery of about 95% of core menu items within 30 minutes for a $0.49 delivery fee and 15% service fee (minimum $2 fee).</li> <li>Shares of SBUX are <font color=\"red\">down 0.48%</font> premarket to $87.02, trading just off their all-time high of $87.95.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3476437\" data-linked=\"Starbucks adds new markets to delivery program\" data-tweet=\"$SBUX - Starbucks adds new markets to delivery program https://seekingalpha.com/news/3476437-starbucks-adds-new-markets-to-delivery-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3476437-starbucks-adds-new-markets-to-delivery-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476435\" data-ts=\"1562674299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKYW\" target=\"_blank\">SKYW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476435-skywest-traffic-grew-8_6-in-june\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SkyWest traffic grew 8.6% in June</a></h4><ul> <li>SkyWest (NASDAQ:<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a>) <a href=\"https://seekingalpha.com/pr/17565449-skywest-inc-reports-june-2019-traffic\" sasource=\"qp_sum_news_2\" target=\"_blank\">reports</a> total block hours rose 8.6% to 127.415K in June.</li><li>Departures advanced 7.1% to 73,104.</li><li>Passengers flown increased 10% to 3.952M.</li><li>June load factor expanded 170 bps to 86%.</li><li>YTD load factor up 60 bps to 81.4%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476435\" data-linked=\"SkyWest traffic grew 8.6% in June\" data-tweet=\"$SKYW - SkyWest traffic grew 8.6% in June https://seekingalpha.com/news/3476435-skywest-traffic-grew-8_6-in-june?source=tweet\" data-url=\"https://seekingalpha.com/news/3476435-skywest-traffic-grew-8_6-in-june\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476433\" data-ts=\"1562674250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNN\" target=\"_blank\">LNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476433-lindsay-profit-slips-misses-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lindsay profit slips, misses estimates</a></h4><ul><li>Adjusted net earnings for FQ3 were $5.5M, or $0.50 per diluted share vs. $17.9M, or $1.66 a year earlier.</li><li>Irrigation segment revenues came in at $98.6M, a decrease of $29.8M, or 23%, compared to $128.4M in the prior year's quarter. Infrastructure segment revenues for the third quarter of fiscal 2019 were $22.4M, a decrease of $18.7M, or 45%, compared to $41.2M in the prior year third quarter.</li><li>Backlog of unshipped orders at May 31, 2019 was $42.5M vs. $55.8M a year earlier.</li><li>Outlook: \"Severe wet weather and widespread flooding in the U.S. have caused delayed corn plantings and curtailed planted acreage, reducing supply estimates and driving a recent increase in corn prices. Any further reduction in supply and increase in corn prices supports an improved outlook for irrigation equipment demand,\" said CEO Tim Hassinger. \"The short-term outlook for international markets remains mixed, with growth expected in Brazil and developing markets while certain other markets remain challenged.\"</li><li><a href='https://seekingalpha.com/symbol/LNN' title='Lindsay Corporation'>LNN</a> <font color=\"red\">-3.6%</font> premarket</li><li><a href=\"https://seekingalpha.com/news/3476398-lindsay-eps-misses-0_26-misses-revenue\" target=\"_blank\">FQ3 results</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3476433\" data-linked=\"Lindsay profit slips, misses estimates\" data-tweet=\"$LNN - Lindsay profit slips, misses estimates https://seekingalpha.com/news/3476433-lindsay-profit-slips-misses-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3476433-lindsay-profit-slips-misses-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476426\" data-ts=\"1562673554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARTL\" target=\"_blank\">ARTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476426-cowen-softens-view-on-myriad-genetics-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen softens view on Myriad Genetics in premarket analyst action</a></h4><ul><li>Artelo Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ARTL' title='Artelo Biosciences, Inc.'>ARTL</a>) initiated with Buy rating and $8 (113% upside) price target at Maxim Group.</li><li>Apellis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a>) initiated with Outperform rating and $52 (101% upside) at Oppenheimer.</li><li>Intellia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics, Inc.'>NTLA</a>) initiated with Outperform rating and $23 (40% upside) price target at Baird.</li><li>NextCure (NASDAQ:<a href='https://seekingalpha.com/symbol/NXTC' title='NextCure, Inc.'>NXTC</a>) initiated with Buy rating and $25 (59% upside) price target at BofA/Merrill Lynch.</li><li>Myriad Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a>) downgraded to Market Perform at Cowen and Company. Shares down <font color=\"red\">2%</font> premarket.</li><li>CannTrust Holdings (TRST CN) downgraded to Market Perform with a C$6 (20% upside) price target at BMO. Downgraded to Neutral with a C$6 price target at Eight Capital. On the U.S. side, downgraded to Neutral with a $4 (4% upside) price target at ROTH Capital.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476426\" data-linked=\"Cowen softens view on Myriad Genetics in premarket analyst action\" data-tweet=\"$ARTL $NXTC $APLS - Cowen softens view on Myriad Genetics in premarket analyst action https://seekingalpha.com/news/3476426-cowen-softens-view-on-myriad-genetics-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3476426-cowen-softens-view-on-myriad-genetics-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476427\" data-ts=\"1562673257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LTM\" target=\"_blank\">LTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476427-latam-airlines-announces-june-traffic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LATAM Airlines announces June traffic</a></h4><ul><li>LATAM Airlines Group (NYSE:<a href='https://seekingalpha.com/symbol/LTM' title='LATAM Airlines Group S.A.'>LTM</a>) <a href=\"https://seekingalpha.com/filing/4560474\" sasource=\"qp_sum_news_3\" target=\"_blank\">reports</a> passenger traffic rose 7% to 9.57B kilometers in June.</li><li>The carrier's capacity advanced 3.5% to 11.52B available seat kilometers.</li><li>Load factor improved 270 bps to 83% for the month.</li><li>YTD load factor up 30 bps to 83.8%.</li><li>International passenger traffic accounted for ~58% of total passenger traffic.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476427\" data-linked=\"LATAM Airlines announces June traffic\" data-tweet=\"$LTM - LATAM Airlines announces June traffic https://seekingalpha.com/news/3476427-latam-airlines-announces-june-traffic?source=tweet\" data-url=\"https://seekingalpha.com/news/3476427-latam-airlines-announces-june-traffic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476414\" data-ts=\"1562672479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476414-dialysis-firms-under-early-pressure-on-trump-plan-to-shake-up-kidney-care-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dialysis firms under early pressure on Trump plan to shake up kidney care market</a></h4><ul><li>Dialysis services providers DaVita (NYSE:<a href='https://seekingalpha.com/symbol/DVA' title='DaVita Inc.'>DVA</a>) and Fresenius Medical Care (NYSE:<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGaA'>FMS</a>) are down <font color=\"red\">1%</font> and <font color=\"red\">3%</font>, respectively, premarket (both on light volume) on the heels of a <a href=\"https://www.politico.com/amp/story/2019/07/08/trump-kidney-care-market-1573651\" target=\"_blank\">report</a> from Politico that the Trump administration is planning to announce initiatives aimed at encouraging more kidney transplants and home-based treatment. The President is scheduled to unveil the strategy in a Wednesday morning speech. He is also mulling additional actions via executive order.</li><li>Concurrently, the U.S. Department of Health and Human Services &#40;HHS&#41; will announce new reimbursement models to incentivize a shift away from standalone clinics to the home, in addition to an agency-wide initiative to encourage home dialysis and better prevention and screening for kidney disease.</li><li>U.S. dialysis clinics generated $24B in revenue last year, mostly by DVA and FMS. Medicare spends more than $114B per year on kidney care.</li><li>Related ticker: American Renal Associates (NYSE:<a href='https://seekingalpha.com/symbol/ARA' title='American Renal Associates Holdings, Inc.'>ARA</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476414\" data-linked=\"Dialysis firms under early pressure on Trump plan to shake up kidney care market\" data-tweet=\"$DVA $FMS $ARA - Dialysis firms under early pressure on Trump plan to shake up kidney care market https://seekingalpha.com/news/3476414-dialysis-firms-under-early-pressure-on-trump-plan-to-shake-up-kidney-care-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3476414-dialysis-firms-under-early-pressure-on-trump-plan-to-shake-up-kidney-care-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476417\" data-ts=\"1562672129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSD\" target=\"_blank\">CLSD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476417-clearside-bio-up-2-premarket-on-suprachoroidal-space-microinjector-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clearside Bio up 2% premarket on Suprachoroidal Space Microinjector deal</a></h4><ul> <li>Clearside Biomedical (NASDAQ:<a href='https://seekingalpha.com/symbol/CLSD' title='Clearside Biomedical, Inc.'>CLSD</a>) has <a href=\"https://seekingalpha.com/pr/17565386-clearside-biomedical-announces-license-agreement-aura-biosciences-suprachoroidal-space\" target=\"_blank\">entered</a> into a worldwide licensing agreement with Aura Biosciences for the use of its Suprachoroidal Space &#40;SCS&#41; Microinjector to deliver Aura\u2019s drug candidates into the SCS for the treatment of certain ocular cancers, including choroidal melanoma.</li>   <li>Aura is licensing Clearside\u2019s SCS Microinjector as a potential non-surgical alternative to intravitreal delivery of its anti-cancer drug candidates. If the collaboration proves successful, Aura may utilize the SCS Microinjector for certain future development programs.</li>    <li>Pursuant to the licensing agreement, Clearside is eligible to receive pre-specified milestone payments, as well as royalties on product sales that utilize the SCS Microinjector.</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3476417\" data-linked=\"Clearside Bio up 2% premarket on Suprachoroidal Space Microinjector deal\" data-tweet=\"$CLSD - Clearside Bio up 2% premarket on Suprachoroidal Space Microinjector deal https://seekingalpha.com/news/3476417-clearside-bio-up-2-premarket-on-suprachoroidal-space-microinjector-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3476417-clearside-bio-up-2-premarket-on-suprachoroidal-space-microinjector-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476416\" data-ts=\"1562671859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476416-3mminus-1-rbc-says-reputation-eroding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3M -1% as RBC says reputation &#39;eroding&#39;</a></h4><ul><li>Following a <font color=\"red\">3.3% slide</font> over the last two trading days, analyst Deane Dray at RBC Capital <a href=\"https://www.thestreet.com/investing/stocks/3m-shares-slide-after-rbc-cuts-price-target-lowers-rating-to-sector-perform--15012691\" target=\"_blank\">lowered</a> his rating on 3M (NYSE:<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a>) to Sector Perform from Outperform, while slashing his PT on shares by 15% to $176.</li><li>After an \"unsettling string\" of guidance cuts, 3M's reputation as a \"defensive, high-quality industrial is eroding,\" he wrote in a research note.</li><li>3M shares are <font color=\"red\">down another 1.3%</font> premarket on the news, a move that would extend the stock's YTD <font color=\"red\">decline to around 12.5%</font>.</li><li>Most <a href=\"https://seekingalpha.com/symbol/MMM/ratings/sell-side-ratings\" target=\"_blank\">sell-side analysts</a> and <a href=\"https://seekingalpha.com/symbol/MMM/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors</a> have a Hold rating on MMM, while the stock has a <a href=\"https://seekingalpha.com/symbol/MMM/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> of Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476416\" data-linked=\"3M -1% as RBC says reputation &#39;eroding&#39;\" data-tweet=\"$MMM - 3M -1% as RBC says reputation &#39;eroding&#39; https://seekingalpha.com/news/3476416-3mminus-1-rbc-says-reputation-eroding?source=tweet\" data-url=\"https://seekingalpha.com/news/3476416-3mminus-1-rbc-says-reputation-eroding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476410\" data-ts=\"1562671436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALT\" target=\"_blank\">ALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476410-altimmune-up-10-premarket-on-acquisition-of-spitfire-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altimmune up 10% premarket on acquisition of Spitfire Pharma</a></h4><ul><li>Thinly traded nano cap Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) is up <font color=\"green\">10%</font> premarket on modest volume on the heels of its <a href=\"https://seekingalpha.com/pr/17565367-altimmune-signs-definitive-agreement-acquire-spitfire-pharma-inc-adding-nash-drug-candidate\" target=\"_blank\">announcement </a>that it has agreed to acquire Spitfire Pharma for up to $93M.</li><li>Under the terms of the deal, Spitfire shareholders will receive $5M in ALT common stock upfront, up to $8M in regulatory and clinical milestones (either cash or ALT stock) and up to $80M in sales-based milestones.</li><li>The top prize is pipeline candidate <a href=\"https://www.prnewswire.com/news-releases/spitfire-pharmas-sp-1373-outscored-semaglutide-and-elafibranor-in-a-biopsy-proven-translational-mouse-model-of-non-alcoholic-steatohepatitis-nash-300577698.html\" target=\"_blank\">SP-1373</a> (to be renamed ALT-801), a GLP-1/Glucagon receptor co-agonist for the treatment of nonalcoholic steatohepatitis &#40;NASH&#41;.</li><li>ALT will host a conference call this morning at 8:30 am ET to discuss the transaction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476410\" data-linked=\"Altimmune up 10% premarket on acquisition of Spitfire Pharma\" data-tweet=\"$ALT - Altimmune up 10% premarket on acquisition of Spitfire Pharma https://seekingalpha.com/news/3476410-altimmune-up-10-premarket-on-acquisition-of-spitfire-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3476410-altimmune-up-10-premarket-on-acquisition-of-spitfire-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476407\" data-ts=\"1562670694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHEK\" target=\"_blank\">CHEK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476407-check-caps-c-scan-beats-reference-test-in-study-shares-up-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Check-Cap&#39;s C-Scan beats reference test in study; shares up 20% premarket</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17565275-check-cap-announces-positive-final-results-post-ce-approval-study-c-scan-system\" target=\"_blank\">Results</a> from Check-Cap's (NASDAQ:<a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a>) post-CE approval study evaluating the screening performance of C-Scan to detect precancerous polyps in the colon showed much better performance compared to the fecal immunochemical test &#40;FIT&#41;.</li><li>The data were generated from 90 patients who either had known polyps or were considered to be at average risk. Each ingested a C-Scan capsule in additional to undergoing a FIT test and colonoscopy.</li><li>In patients with polyps at least 10 mm in size, the sensitivity (correctly identifying true positives) of C-Scan was 76% compared to 29% for FIT. C-Scan's specificity (correctly identifying true negatives) was 82% versus 96% for FIT in these patients.</li><li>In all patients, C-Scan's sensitivity was 66% compared to 23% for FIT.</li><li>A U.S. <a href=\"https://clinicaltrials.gov/ct2/show/study/NCT03735407?term=Check-Cap&amp;show_desc=Y#desc\" target=\"_blank\">pilot study</a> is in process with an estimated completion date in September. A pivotal trial should launch in mid-2020.</li><li><strong>Update</strong>: Shares are up <font color=\"green\">20%</font> premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3476407\" data-linked=\"Check-Cap&#39;s C-Scan beats reference test in study; shares up 20% premarket\" data-tweet=\"$CHEK - Check-Cap&#39;s C-Scan beats reference test in study; shares up 20% premarket https://seekingalpha.com/news/3476407-check-caps-c-scan-beats-reference-test-in-study-shares-up-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3476407-check-caps-c-scan-beats-reference-test-in-study-shares-up-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476391\" data-ts=\"1562667765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEP\" target=\"_blank\">PEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476391-pepsico-beat-q2-bottom-line-estimates-reaffirms-fy2019-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PepsiCo beat Q2 bottom-line estimates, reaffirms FY2019 outlook</a></h4><ul><li>PepsiCo (NASDAQ:<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo, Inc.'>PEP</a>) reports organic revenue growth of 4.5% in <a href=\"https://seekingalpha.com/pr/17565260-pepsico-reports-second-quarter-2019-results\" target=\"_blank\">Q2</a>.</li><li>Foreign exchange impact on revenue was -3%.</li><li>Revenue by segment: Frito-Lay North America: $4.01B (+4.5%); Quaker Foods North America: $540M (+2.5%); Latin America: $1.89B (+2%); North America Beverages: $5.32B (+2.5%); Europe Sub-Saharan Africa: $3.13B (+0.5%); AMENA: $1.56B (-1%).</li><li>Total core gross margin rate improved 70 bps to 55.5%.</li><li>Total core operating margin rate dropped 130 bps to 17.7%.</li><li><b>FY2019 Guidance</b>: Organic revenue growth: 4%; Core EPS: $5.50; Tax rate: ~21%; Net capital expenditure: ~$4.5B; Cash flow from operating activities: ~$9B; Free cash flow: ~$5B.</li><li>PEP<font color=\"red\"> </font><font color=\"green\">+0.48%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3476388-pepsico-eps-beats-0_03-revenue-line\" target=\"_blank\">PepsiCo EPS beats by $0.03,  revenue in-line</a> (July 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3476391\" data-linked=\"PepsiCo beat Q2 bottom-line estimates, reaffirms FY2019 outlook\" data-tweet=\"$PEP - PepsiCo beat Q2 bottom-line estimates, reaffirms FY2019 outlook https://seekingalpha.com/news/3476391-pepsico-beat-q2-bottom-line-estimates-reaffirms-fy2019-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3476391-pepsico-beat-q2-bottom-line-estimates-reaffirms-fy2019-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3476390\" data-ts=\"1562667713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABB\" target=\"_blank\">ABB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3476390-big-charges-abb-offloads-solar-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big charges as ABB offloads solar business</a></h4><ul><li>ABB (NYSE:<a href='https://seekingalpha.com/symbol/ABB' title='ABB Ltd'>ABB</a>) will <a href=\"https://www.reuters.com/article/us-abb-solar-divestiture-idUSKCN1U40E8?utm_campaign=trueAnthem%3A+Trending+Content&amp;utm_content=5d2452038e73cc0001643987&amp;utm_medium=trueAnthem&amp;utm_source=twitter\" target=\"_blank\">pay</a> up to $470M to hand over its loss-making solar inverter business to Italy\u2019s FIMER, highlighting the tough conditions in the solar industry where prices have fallen in the face of Chinese competition and increased production.</li><li>An after-tax non-operational charge of approximately $430M wil be taken in the second quarter of 2019 to get rid of the business, with up to three quarters of the money being cash paid to FIMER.</li><li>An extra $40M will come in separation costs, ABB added, with the deal due to be completed in the first quarter of 2020.</li><li>ABB <font color=\"red\">-2.5%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3476390\" data-linked=\"Big charges as ABB offloads solar business\" data-tweet=\"$ABB - Big charges as ABB offloads solar business https://seekingalpha.com/news/3476390-big-charges-abb-offloads-solar-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3476390-big-charges-abb-offloads-solar-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":68,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}